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Abstract  
 
The plant produced HCV-E1 viral proteins could be using for further studies about the 
vaccine development and doing the molecular studies about the potential for produce the 
edible vaccine against HCV. The successful vaccines against Hepatitis C virus have required 
the production of antibodies, “Identifying regions of the virus that are able to induce broadly 
reactive neutralizing antibodies is a significant milestone in the development of a HCV 
vaccine, which will have distinct healthcare benefits for hepatitis sufferers, and could also 
help us design vaccines for other chronic viral diseases such as HIV.". The antibodies can 
improve liver transplantation success rates by passively infusing people with these antibodies, 
and using the information gained by identifying and characterizing the antibody responses to 
Hepatitis C virus E1 structural protein to design new ways of making vaccine candidates. In 
this study, I show the produce and purify the recombinant full size and truncated fragments of 
HCV-E1 glycoprotein in E. coli. The monoclonal antibodies were generated against the 
recombinant E1 full size protein via hybridoma technology. Further characterization of the 
monoclonal antibodies by E1 truncated fragments. The single variable chain antibody was 
generated specific to the recombinant E1 protein, for characterize and improve E1 production. 
The specific monoclonal antibodies against the recombinant E1 protein were used in 
diagnoses of HCV in infected patient serum as using sandwich ELISA. 
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I Introduction 
I.1 Hepatitis C virus  
Hepatitis C virus (HCV) is a silent virus, i.e. most people are unaware of its presence even 
decades after infection. More than 170 million people around the world are infected with 
HCV, often through contact with infected blood [1]. After 20 years of investigation, the 
World Health Organization (WHO) reported that ~3% of the world's population is chronically 
infected with HCV (Figure 1), and four million new infections occur each year. HCV causes 
chronic hepatitis C and ultimately death by liver cirrhosis or hepatocellular carcinoma. 
Several factors are associated with fibrosis progression, including the duration of the 
infection, and the age, gender and alcohol consumption of the patient [2]. HCV is divided into 
six major genetic groups designated “genotypes” based on the genome sequence. The more 
closely related HCV strains within same genotype are designated “subtypes”. The diverse 
genetic variants found in individual patients are described as “quasispecies”. It is thought that 
viral quasispecies play a role in the progression and pathogenesis of HCV infections. HCV is 
present in patients as a pool of viruses representing different epitopes [3]. HCV is spread 
mainly by needle sharing, tattoos and piercings, mother-to-child transmission, unprotected 
sexual transmission, sharing items such as toothbrushes or razors and occupational exposure 
[4, 5]. HCV genotype 4 is a major health problem in Egypt, and the entire continent of Africa 
(Table 1) [6].  
        Table.1: Worldwide distribution of HCV genotypes 
 
 HCV Genotype Distribution 
1, 2, 3 Worldwide 
4 Middle East, Africa and Egypt 
5 South Africa 
6 Southeast Asia 
 
 
HCV infection causes acute liver disease, progressing from mild symptoms to cirrhosis and 
hepatocellular carcinoma (HCC) in 20-30 years. In addition, HCV infection rates differ in 
different settings, and prognosis may be worse when it is present in conjunction with 
schistosomiasis [7]. 
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Figure 1: Picture shows the worldwide widespread presence of HCV. Africa and Asia were reported highest 
prevalence ratios in contrast to low ratios in North America, Western Europe, and Australia. Egypt has a 
powerful prevalence of hepatitis C, 20% of Egyptian blood givers been positive for HCV antibody. Prior 
parenteral treatment for Schistosomiasis with short sterilization techniques has been involved as the source for 
this high widespread presence ratio. Similar epidemiological occurrences explain the point in infection ratios in 
other countries, for example, Germany‟s HCV prevalence ratio of 4%. Japan‟s prevalence ratio of 2.6% is 
thought to be secondary to the injection of methamphetamines World Health Organization, 2002. 
 
The prevalence of HCV varies by region, with the greatest number of infections in Egypt. The 
use of parenteral antischistosomal therapy in Egypt is thought to have contributed to the 
prevalence of antibodies against HCV in various regions, ranging from 6 to 28% (mean, 22%) 
of the population [8]. In the USA, 1.8% of the population carries HCV antibodies. HCV has 
emerged as a major health problem in the USA and is now the most common blood borne 
infection up to 1.6% of the population (4.1 million people) are seropositive. These persistently 
infected individuals are the source of the majority of new HCV infections. However, HCV 
treatment is expensive and prolonged and is often unsuccessful [9]. It is unlikely that the 
number of carriers will be reduced significantly by antiviral therapy in the near future [10].  
 
I.2      HCV genetic diversity and genome organization 
HCV is an enveloped virus from the family Flaviviridae, with a single stranded, positive sense 
RNA genome approximately 9.4 kb in length. The genome contains a single open reading 
frame (ORF) and highly conserved untranslated regions (UTRs) at the 5′ and 3′ ends. The 
HCV ORF encodes a polyprotein ~3000 amino acids in length (Figure 2) [11]. HCV is 
heterogeneous in sequence reflecting the introduction of random nucleotide errors by RNA 
polymerase during replication. Isolates of the same genotype have an average sequence 
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identity of 95% (range 88-100%). The subtypes within the same genotype have an average 
sequence identity of 80% (range 70-85%) [12]. The RNA genome is subject to considerable 
variability, at least six different genotypes having been identified, each nucleotide sequence 
differing by ~30% [13]. Isolates derived from individual patients at specific time points are 
also subject to variability [14]. The significance of HCV quasispecies was determined by 
correlating their presence with clinical manifestations of HCV infection, such as the 
development of liver disease, response to interferon therapy and viral load in the serum [15]. 
It has been suggested that the increasing complexity of quasispecies variants is associated 
with a relative lack of interferon responsiveness and that some quasispecies variants are more 
resistant to interferon than others [16]. The major structural proteins of the virus are the core 
protein and the envelope proteins E1 and E2. The core protein forms the nucleocapsid of the 
mature virion, whereas E1 and E2 are present in the viral envelope. The non-structural 
proteins are NS2, NS3, NS4A, NS4B, NS5A and NS5B [17].  
 
 
NS 3  cleavage 
Cellular signal peptidase 
Non - structural proteins 
Structural proteins 
~     9,600  bases (+) RNA 5 `NCR 3 `NCR 
C E 1 E 2 NS 2 NS 3 NS 4 B NS 5 A NS 5 B 
Figure 2: Genetic organization and polyprotein processing of the hepatitis C virus. The 9.6-kb positive-
strand RNA genome is schematically represented at the top. The RNA secondary structures in the 5′- and 3′-non-
coding regions (NCRs) and the core gene, as well as the NS5B stem-loop cis-acting replication element (5B-
SL3) are displayed. Internal ribosome entry site (IRES)-mediated translation products a polyprotein indication 
which is processed into the mature structural and non-structural proteins. The brown arrows indicate cleavage 
sites of the HCV polyprotein precursor by the endoplasmic reticulum signal peptidase. The blue diamond 
indicates further C-terminal processing of the core protein by signal peptide peptidase [18] 
 
I.3 The HCV life cycle 
I.3.1 Attachment and entry 
Both viral and host cell components are required for HCV attachment and entry. Hepatocytes 
are the main target cells for HCV infection, but the virus has also been found in B cells, 
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dendritic cells, and other cell types. HCV penetrates liver cells by integrating into the cell 
membrane [19]. The E1 and E2 integral membrane proteins are glycosylated noncovalent 
heterodimers, with E2 apparently responsible for viral attachment [20]. The process starts 
when HCV binds to receptors on the hepatocyte surface followed by endocytosis (Figure 3). 
CD81 was the first receptor shown to mediate the uptake of HCV into liver cells [21]. Entry 
may be facilitated when virions associate with β-lipoproteins via interactions between the 
capsid core protein, apolipoprotein AII and intracellular lipid droplets. Notably, the 
expression of LDL receptors in some cell types was shown to induce HCV binding. The 
endocytosis of HCV particles appears to be mediated by the LDL receptor, but may be 
promoted by other interactions [22]. CD81 is found on the surface of many cell types, and is 
thought to interact with E2 to mediate HCV uptake [23]. It is not clear whether CD81 alone is 
enough to promote virus uptake [24]. and many studies suggest CD81 and E2 are not the only 
proteins involved [25]. Other proposed HCV receptors in addition to LDL and CD81 include 
scavenger receptor class B type I (SR-BI), dendritic cell-specific intercellular adhesion 
molecule-3-grabbing nonintegrin (DC-SIGN), liver/lymph node-specific intercellular 
adhesion molecule-3-grabbing integrin (L-SIGN), and more recently, claudin-1 which is 
essential for HCV uptake into hepatic cells and has been termed a coreceptor [26]. The E2 
glycoprotein is insufficient for membrane fusion, and a hydrophobic region of the E1 
glycoprotein may stimulate fusion between the viral envelope and cell membrane [23, 27]. It 
is suggested that low pH may also facilitate HCV uptake into target cells by receptor-
mediated endocytosis [28]. 
 
I.3.2 Translation and processing of HCV 
There is no evidence that HCV genomic RNA carries either the 5'-methylguanidine cap or 3'-
polyadenylate tail typical of eukaryotic mRNAs, but it is nevertheless sufficient to direct 
translation of the polyprotein [12]. The 5'-UTR folds into a complex secondary tertiary RNA 
structure, and is notably one of the few regions of the genome that is highly conserved among 
all HCV genotypes. The 300 nt region upstream of the initiator codon functions as an internal 
ribosome entry site (IRES), directly recruiting the 40S ribosomal subunit to the start codon 
[29, 30]. 
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Figure 3: Life cycle of hepatitis C virus. Virus wrapping and internalisation (a); cytoplasmic deliverance and 
uncoating (b); IRES-mediated translation and polyprotein preparing (c); RNA replication (d); wrapping and 
collection (e); virion maturation and loose (f). The topology of HCV structural and non-structural proteins at the 
endoplasmic reticulum membrane are indicated schematically. HCV RNA replication develops in a specific 
membrane modification. IRES-mediated translation and polyprotein preparing as well as membranous web 
formation and RNA replication, which are clarified here as different steps for simplexes might occur in a tightly 
paired fashion. IRES, internal ribosome entry site [31]. 
 
The first 40 nt of the 5'-UTR comprise a stem-loop structure and the region between 
nucleotides 38 and 46 has been identified as the 5′ boundary of the IRES, which initiates 
translation [29]. Among the 5′-UTR domains are complex structures like domain IV, 
comprising a small hairpin that contains the AUG start codon at nt 342 [32]. The viral 
polyprotein is cotranslationally integrated into the ER membrane, where it undergoes 
proteolytic processing during and after synthesis mediated by both host and viral proteases. 
The host signal peptidase, resident in the ER lumen, is responsible for cleavage between the 
HCV structural proteins and separation at the p7/NS2 junction. The E1 and E2 proteins are 
translocated into the ER lumen, with the C-terminal domains remaining embedded in the 
membrane. The nonstructural proteins are cleaved by the activity of two viral serine proteases, 
NS2 and NS3-4A [33]. HCV RNA replication has been investigated using subgenomic HCV 
replicons [34]. The polyprotein is processed into 10 mature proteins, with further alternative 
reading frame protein (ARFP) created by ribosomal frame-shifting within the core protein 
gene [35]. 
 
I.3.3 Replication 
The RNA polymerase activity responsible for HCV RNA synthesis is encoded in the NS5B 
region, which is sufficient for the in vitro synthesis of full-length HCVRNA. The HCV3'-
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UTR contains a variable length polypyrimidine sequence (U/UC) that terminates in a highly 
conserved sequence 98 nt in length [36]. The hydrophobic C-terminal portion of NS5B 
localizes with the conserved UTR sequence into perinuclear membrane-associated complexes 
that form a membranous web, potentially derived from the ER, at the site of RNA replication 
[37]. This sequence is used as a template to generate a complementary RNA strand, which in 
turn is used to generate multiple copies of the positive strand RNA genome [38]. Each 
negative strand yields 5-10 copies of the positive strand genome and other factors in addition 
to NS5B are required for, or improve the efficiency of, this process [39]. As the RNA 
replicons accumulate, mutations begin the process of adaptation to increase the efficiency of 
colony formation. Mutations are often detected in the sequences encoding NS5B part, the 
mutations in NS5A facilitate adaptations that increase the efficiency of replication 
independent of the sensitivity to IFN [40]. Liver cells often contain subgenomic replicons that 
express structural proteins and nonstructural polyproteins, inducing similar changes to the 
membrane [41]. All HCV structural and nonstructural proteins are associated with the ER 
membrane in cells containing subgenomic replicons [18].  
 
I.3.4 Virus assembly and release 
The HCV positive strand binds cotranslationally to the core protein and NS5B, suppressing 
IRES activity and causing the transition from replication to assembly [42]. The ER-derived 
membrane does not affect the formation of HCV capsid protein, but the core protein is 
essential for capsid protein assembly, as in other members of the Flaviviridae [31]. The 
envelope glycoprotein E1 contains five or six N-linked glycosylation acceptor sites, whereas 
E2 contains 11 [43]. The core, E1, E2 and p7 proteins released from the polyprotein then 
interact non-covalently to form a complex, and their C-terminal transmembrane domains 
penetrate the ER membrane [44]. The C-terminal domain of E2 is an ER retention signal, 
preventing translocation to the Golgi apparatus until the cell surface is incorporated into the 
virion envelopes. HCV core RNA particles are therefore thought to bud through the ER 
membrane instead of the plasma membrane [45]. Interactions between the core and E1/E2 
proteins determine the morphology of the HCV virion [46]. HCV-like particles can assemble 
within intracellular vesicles and then bud from the ER [47]. Interactions between the core and 
E1 proteins occur in a specific sequence and depend on hydrophobicity, although self-
assembly of the core protein and E1 requires the cytoplasmic loop of the polytopic form of the 
E1 protein [48]. HCV particles are then released from the cell through the secretory pathway. 
HCV structural proteins have been observed in the ER and Golgi apparatus, and complex N-
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linked glycans added in the Golgi have been detected on HCV particles isolated from serum 
[49].  
I.4 HCV treatment 
The standard treatment of chronic hepatitis C involves the administration of pegylated 
interferon and ribavirin, a regimen that has evolved over the last 18 years [50]. Although 
interferon (IFN) suppresses HCV replication, the exact mechanism is unknown. Clearance 
may be mediated in part by IFN-related enhancement of the host immune response to the 
virus [51]. Ribavirin (1- β-D-ribofuranosyl-1H-1, 2, 4-triazole-3-carboxamide) is a synthetic 
nucleoside analogue which structurally resembles guanosine and is active against many 
viruses in vitro, including Flaviviridae. A combination of interferon alfa-2B and ribavirin can 
delay progression towards liver cirrhosis [52]. Unfortunately, combination therapy causes 
severe off-target effects (21% of patients withdraw before the 48 weeks of treatment is 
complete). Interferon has an immediate effect on the virus (relapse occurs within 48 h) and is 
usually administered three times weekly [53].  Standard interferon has a limited impact on the 
virus between doses, but a high molecular weight version (40 kDa) containing branched 
polyethylene glycol (PEG) is absorbed and cleared more slowly [54], such that IFN can still 
be detected in patient serum one week after treatment [55]. A combination of interferon alfa-
2B and ribavirin (IFN-R) is more effective than IFN alone, reducing hepatic inflammation 
independent of the virological response [56]. IFN-R can reduce the development of chronic 
HCV in constant virological responders [57].  
I.5 Potential role of E1 glycoprotein in the virus life cycle and replication 
The E1 envelope glycoprotein is required for virus entry into liver cells, and it induces 
neutralizing antibodies against HCV. There is a positive and quantitative correlation between 
the E1 antigen and the enzymes aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT), which are associated with inflammation and/or injury to liver cells in 
HCV patients [58]. Amino acids 270 to 284 in the E1 glycoprotein are necessary for 
membrane fusion, either interacting directly with lipid membranes or facilitating the fusion 
process by promoting conformational changes within the E1 complex at low pH [59]. This 
region therefore constitutes an E1 fusion peptide-like domain, which influences membrane 
fusion and HCV uptake [60]. E1 binds to receptors during host cell recognition and induces 
fusion with the host cell membrane to promote uptake and the onset of infection. The E1 N-
terminal sequence YEVRNVSGVYH can immunoprecipitate E1E2 heterodimers [61]. E1 
protein modification and/or folding is required for virus-receptor interactions during 
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recognition and attachment [62]. Amino acids 315 to 327 are highly conserved in most HCV 
strains, and may play a role in membrane destabilization by forming and enlarging membrane 
pores [63]. The most conserved region of the E1 glycoprotein is an optimal target for anti-
viral drugs. The putative fusion peptide (FP) (amino acids 259-298) and the C-terminal region 
of E1 interact in the post-fusion structure, so this post-fusion FP-TM complex represents an 
important function of the E1 protein in the virus life cycle [64].  
 
1.6 The ER membrane and the translocation protein 
E1 glycoprotein did not contact the cell membrane but accumulate in the endoplasmic 
reticulum. Moreover, contain stretches of hydrophobic residues that potentially function as 
transmembrane domains [65]. E1-specific immune responses can be induced in resolving 
HCV infections, and memory cells can be stimulated using suboptimal doses of the E1 
antigen [66]. Four to five potential N-glycosylation sites are strongly conserved among HCV 
genotypes [67]. A sequence that may induce membrane destabilization is found immediately 
adjacent to the transmembrane domain [68]. In addition to their role in virus uptake, HCV 
envelope glycoproteins are also involved in later infection cycle steps such as particle 
assembly. These functions can now be investigated ex vivo following the development of the 
HCV cell culture system [69]. Uptake into cells is a critical step in the life cycle of a virus, 
and therefore represents a target that can be blocked by neutralizing antibodies or antiviral 
drugs that target the envelope proteins. The HCV envelope glycoproteins are retained in the 
ER via the retention signal present in the transmembrane domain of E1 [70]. One or more 
hydrophilic residues are also present within the E1 transmembrane domain [71]. An  
additional ER retention signals might be present in the E1 ectodomain [43]. The interaction 
between the core and the E1 proteins probably takes place while the proteins are associated 
with the ER membrane [48].  
 
I.7 Recombinant expression of therapeutic proteins 
Recombinant pharmaceutical proteins (biopharmaceuticals) represent a growing sector of the 
pharmaceuticals market. Globally, more than 125 recombinant proteins have been approved 
for medical use with a market exceeding US$ 56 billion annually, and more than one third of 
these biopharmaceuticals are antibodies or products based on antibodies [72]. The 
development pipeline is brimming with candidates, with more than 1500 recombinant protein 
drugs or vaccines undergoing clinical trials, 387 of which are currently in the patient 
recruitment phase. With no sign of the market declining in the near/mid-term, robust protein 
expression platforms are required that account for codon use differences between the host and 
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source of the protein, the expected yield, the need for productive folding and post-
translational modifications, and the requirement for efficient downstream processing, scale-up 
and productivity [73]. Production in clinical development must also satisfy good 
manufacturing practice (GMP) requirements. Currently, most commercial recombinant 
proteins are produced in microbes or mammalian cells [74].  
 
I.7.1 Microbial expression system 
The most popular microbial production platform is based on the bacterium Escherichia coli, 
which rose to prominence as a laboratory model organism and was adopted as an expression 
platform because of the extensive body of knowledge concerning its molecular biology and 
genetics, its fast growth in inexpensive defined media, its convenience and simplicity and its 
high volumetric productivity [75]. Like most other prokaryotes, however, E. coli has no 
capacity for post-translational modifications such as glycosylation or the formation of 
disulfide bridges in their cytoplasm [76]. Recombinant proteins tend to aggregate and form 
inclusion bodies in the cytoplasm, so resolubilization in denaturing agents is necessary, 
resulting in incomplete recovery [77,78]. Cell lysis to recover cytoplasmic proteins also 
releases endotoxins that need to be removed from the final product [79]. Many of these issues 
can be avoided by targeting the protein to the periplasmic space using the pelB leader 
sequence, and disulfide bonds can be formed efficiently in this compartment [80]. There are 
also fewer proteases in the periplasm compared to the cytoplasm, and resident chaperones that 
promote folding, overall leading to more stable recombinant proteins that suffer less 
degradation [81]. It so must be using a vector system acceptable for periplasmic expression 
like pET26b(+), and contained the pelB leader sequence to lead the produced protein to the 
periplasm. 
I.7.2 Plant expression system 
Plant-based production systems have also been developed for the synthesis of recombinant 
pharmaceutical proteins in a commercial setting [82]. Plants allow the production of 
inexpensive recombinant proteins because they can be grown on an agricultural scale and they 
do not produce endotoxins or support human pathogens [83]. The first human protein 
produced in plants was albumin [84]. and this has been followed by hundreds of diverse 
therapeutics, diagnostics and vaccine candidates in a range of different crops including leafy 
plants, cereals, potato tubers and fruits, as well as contained systems [84]. Tobacco is 
currently favoured for commercial production because of its unmatched biomass yield and 
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scalability over a short time [85]. Challenges include the lower yields compared to microbial 
and mammalian systems, the presence of non-authentic glycans and the production in some 
plants of toxic secondary metabolites such as phenolics which must be removed during 
downstream processing [86]. As with microbial and mammalian expression systems, 
expression in plants must be tailored and optimized according to the target protein. Promoters 
can be selected to express the protein in a specific tissue or organ, e.g. seeds or seed sections, 
and targeting sequences can direct the protein to compartments such as the apoplast, ER or 
plastids [87]. Elements in the expression cassette can also facilitate protein extraction from 
plant material. The secretory pathway is more appropriate for expression than the cytosol 
because proteins tend to fold and assemble properly in the latter [88]. However, rather than 
secreting the protein to the apoplast, it is often beneficial to retain the protein within the ER 
lumen, which has an oxidizing environment suitable for the formation of disulfide bonds, an 
abundance of molecular chaperones and fewer proteases than other compartments [89]. 
Proteins retained in the ER using a KDEL signal accumulate to higher levels (up to ten-fold 
more) than in other compartments [90]. Furthermore, ER retention also prevents Golgi-
dependent glycans modifications which introduce plant-specific sugar residues; proteins 
retained in the ER contain only high-mannose glycans, which are universal in eukaryotes, and 
this helps to reduce the immunogenicity of human proteins produced in plants [91]. The 
plastid is also a suitable target for recombinant protein accumulation [92]. 
 
I.8 Diagnosis of HCV infection 
HCV was discovered in 1989 in a chimpanzee infected with sera from a human with chronic 
non-A, non-B hepatitis. The use of molecular biology techniques to investigate the virus and 
its infection cycle have led to the development of numerous immunoassays based on different 
HCV antigens and synthetic peptides, which are used to detect and quantify HCV antibodies 
in sera [93]. To increase the sensitivity and specificity of these assays, several antigens are 
routinely included to avoid false positives and detection failures. The first generation of 
immunoassays used a fusion protein from the NS4 region and could detect HCV antibodies 4-
6 months after infection, A second generation of immunoassays were developed using three 
immunodominant HCV antigens, the capsid, NS3 and NS4, allowing diagnosis within 3-12 
weeks of infection [94]. Third generation immunoassays using serological techniques based 
on ELISA and the recombinant immunoblot assay (RIBA) incorporate NS5 in addition to the 
other antigens and have even greater sensitivity, but even these tests are not accurate and 
often produce contradictory results when confirmatory assays are performed at a later stage 
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based on the presence of HCV RNA [95]. Such issues often arise during the acute phase of 
HCV infections when there are low antibody titers, in immunosuppressed patients who lack 
HCV antibodies all together, and among low-risk blood donors with false-positive ELISA 
tests [96]. RIBA and synthetic peptide assays have many advantages, e.g. the inclusion of 
recombinant NS5 and a c22-3 recombinant antigen replaced by core synthetic peptides [97]. 
The development of double antigen sandwich assays using the antigen as both the capture 
component and the tracer has improved sensitivity and specificity even further, with results 
comparable to assays based on HCV-RNA [98]. Despite these improvements, however, the 
following issues remain to be addressed: 
 Improvement of analytical sensitivity and specificity 
 Detection of low antibody titers in infected patients 
 Earlier detection of HCV infection 
 Differentiation between acute and chronic infections 
The quantification of HCV in infected patients has been accomplished using commercially 
available ELISAs [99]. 
  
I.8.1 Use of E1-specific mAbs in diagnostics 
The quantitation of anti-HCV-E1 antibodies in serum should be more useful than viral load 
for the diagnosis of acute HCV infection, because the detection of this protein reflects the 
assembly of HCV particles and subsequent intracellular inflammatory reactions, not only the 
presence of viral RNA [100]. Preclinical studies in chimpanzees have shown that polyclonal 
antibodies derived from the plasma of HCV-infected patients can prevent or delay HCV 
infection if administered before or soon after inoculation with the virus [101]. The specific 
HCV strain determines the severity of liver disease and the response to antiviral therapy. The 
E1 region can be used to predict the most common HCV genotypes and subtypes, therefore 
providing early guidance as to the correct treatment regimen, It is also exposed on the surface 
of the HCV particle, thus representing a promising target for neutralizing antibodies [102]. 
There are at least two regions of E1 glycoprotein containing putative neutralization epitopes, 
an N-terminal region spanning amino acids 192 to 202 identified by epitope mapping [61]. 
and the highly conserved region spanning amino acids 315 to 328, including the almost fully 
conserved residue at position 324 [103]. E1 monoclonal antibodies efficiently neutralize HCV 
pseudoparticles from genotypes 1a, 1b, 4a, 5a and 6a. They neutralize some strains of 
genotypes 2a and 2b, albeit with less efficiency, but do not affect pseudoparticles from 
genotype 3a [104].  
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I.9 Objectives of this study 
HCV is an important human pathogen with a significant impact on global health. Its 
prevalence varies by region, with developing countries bearing the brunt of the disease and 
some with extraordinary infection levels, e.g. 20% in Egypt. Active and passive immunization 
can be used to treat hepatitis A and B, but a vaccine is not available for hepatitis C and post-
exposure prophylaxis only serves to prolong the incubation period without affecting the 
infection or its prognosis. Plant-derived antigens are functionally similar to traditional 
vaccines, and are therefore able to induce neutralizing antibodies in mammals. Genetically 
engineered plants have been used to produce immunogenic peptides, allowing the production 
of oral vaccine candidates in edible plant tissues. The vaccination of chimpanzees with 
recombinant HCV envelope glycoprotein HCV-E1 induced strong antibody responses that 
prevented infection when challenged with a homologous HCV strain. Plants could be used to 
produce E1-based oral vaccines against HCV. The most successful HCV vaccines thus far 
have been those capable of inducing broadly active neutralizing antibodies, a strategy that has 
also been beneficial in other viral diseases. The passive infusion of such antibodies could 
improve the success rate of liver transplants, and could help to define new strategies for the 
development of HCV vaccine candidates. 
The first aim of this study, 
 Production and purification of recombinant full size and truncated fragments of HCV-
E1 glycoprotein in E. coli.  
 Generation of monoclonal antibodies against the recombinant E1 full size protein 
using hybridoma technology.  
 Characterization of recombinant E1-specific antibodies and determining the 
corresponding epitopes.  
 
The second aim 
 Generation and production of a single variable chain antibody specific to recombinant 
E1 protein in E. coli. 
 Production and characterization of E1 and scFv-FM3 in tobacco plants 
 Production of the specific scFv-FM3 in E. coli and tobacco plants.  
 Characterization the binding between the scFv-FM3 and recombinant E1 (from plants 
and bacteria) by ELISA. 
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The third aim 
 Use of monoclonal antibodies against recombinant E1 protein to detect the E1 
glycoprotein in patient sera. 
 Detection of HCV-specific antibodies in patient sera by ELISA. 
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Figure 4: A schematic overview of the Ph.D thesis. 
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II Materials and Methods 
II.1 Materials 
II.1.1 Chemicals and consumables 
The chemicals used throughout the work were purchased from the following companies: Bio-
Rad (München), Roche (Mannheim), Fluka (Neu-Ulm), Gibco BRL (Eggenstein), Merck 
(Darmstadt), Roth (Karlsruhe), Serva (Heidelberg), Sigma (Deisenhofen). The consumables 
were from: Amicon (Witten), Biozym (Hess. Oldendorf), Eppendorf (Hamburg), Greiner 
(Solingen), Kodak (Stuttgart), Millipore (Eschborn), Schott Glaswerke (Mainz), Serva 
(Heidelberg), Stratagene (Dusseldorf), Whatman (Bender & Hobein, Bruchsal) and Zeiss 
(Oberkochem).Novagen (Darmstadt, Germany). 
II.1.2 Enzymes and reaction kits 
Restriction enzymes either from New England Biolabs (Schwalbach) were used for DNA 
digestion. ExpandTM high fidelity DNA Taq polymerase from Roche was used for PCR 
amplification from cDNA libraries. Taq polymerase from Gibco BRL or homemade were 
used for amplification of mouse heavy and light chain fragments and for amplification of 
cloned DNA (“check-PCR”). 
The following kits were used: 
Plasmid isolation kits (Mini, Midi, Maxi) Qiagen (Hilden) 
QIAquick gel extraction kit Qiagen 
QIAquick PCR purification kit Qiagen 
RNeasy mini kit Qiagen 
SuperscriptTM preamplification system kit GibcoBRL 
BCA protein assay kit Pierce (Rockford) 
Bradford protein assay kit Bio-Rad 
Horseradish peroxidase (HRP) conjugation kit Bio-Rad 
II.1.3 Primary antibodies, secondary antibodies and substrates 
Mouse-anti-penta-His [α penta-His Ab] (Qiagen): monoclonal mouse antibody for the 
detection of the C-/N-terminal histidin-tag of recombinant proteins antibodies were also used 
for detection of E1, E1 truncated fragments and scFv-FM3 fragment in bacterial and transient 
plant expression experiments, and was also used as capture antibody for epitope mapping in 
ELISA analyses (II.2.3.5). Rabbit anti-GST polyclonal antibodies provided by plant 
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biotechnology department (Fraunhofer IME, Aachen, Germany) were used for detection of 
GST fusion proteins. Mouse anti-c-myc tag monoclonal antibody (Sigma Aldrich, 
Taufkirchen) was used for detection of scFv-FM3 fragment by immunoblot analysis (II.2.3.3), 
and ELISA (II.2.3.5). Alkaline phosphatase (AP) or horseradish peroxidase (HRP)-conjugated 
to goat anti-mouse IgG (H+L, Fc) (Dianova,Hamburg) antibodies were used as secondary 
antibody in immunoblot analysis (II.2.3.3) and ELISA (II.2.3.5). NBT/BCIP (Bio-Rad) and 
pNPP (Bio-Rad) were used as substrate for detection of immobilized proteins in immunoblot 
(II.2.3.3) and ELISA (II.2.3.5), respectively. 
II.1.4 Bacterial strains 
E. coli strains DH5 and XL1-Blue were used as a host cells for all intermediate cloning 
constructs; BL21 was used for expression of HIS and GST fusion proteins (II.2.3.1). HB2151 
was used for expression of soluble scFv-FM3 fragment (II.2.3.3) (Table 1). 
Table 2: Names, suppliers and genotypes of Escherichia coli strains used throughout the work. 
 
Strain Source Genotype 
DH5α 
Ausubel et al., 
1994 
F- (f80d Lac 2ΔM15)Δ(LacZYA-argF) U169end A1 rec1 
hsdR17(rk
-
 mk
+) deoR thi-1 supE44 gyrA96 relA1 λ- 
HB2151 
Ausubel et al., 
1994 
K12, ara,(lac-pro), thi/ F  ´pro A+B+, lacIqzM15 
BL21(λDE3) 
Novagen 
(Darmstadt) 
F-ompT hsdSB (rB
- mB
-) gal dcm (DE3) 
XL1-Blue 
Stratagene 
(Düsseldorf) 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [FproAB 
laclI
q
ZM15 Tn10 (Tetr)] 
 
Agrobacteria strains: 
Agrobacterium tumefaciens GV 3101 (pMP90RK GmR, KmR, RifR [105] was used for  
agrobacterium-mediated gene transfer (II.2.6.2).  
II.1.5 Plants and animals 
 Nicotiana tabacum L. cv. Petite Havana SR1 was used for transient protein expression 
after vacuum infiltration or syringe injection of agrobacteria (II.2.6.3) (Fraunhofer IME, 
Aachen, Germany). 
 6-8 weeks old female BALB/c mice were used for immunization with E1-His fusion 
protein (II.2.4.1). 
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II.1.6 Vectors 
Schematic presentation of the vector maps are presented in the Appendix. 
 
pMSLGFP-E1, the E1 sequence of HCV genotype 1b (cDNA provided by Dr. Zentgraf, 
DKFZ, Heidelberg, trans-membrane region deleted). 
 
pET26b (+) from Novagen, was used for cloning and purification of recombinant proteins via 
IMAC (immobilized metal ion affinity chromatography) (II.2.2.3). 
 
pGEX-5X-3 from Amersham Pharmacia Biotech, modified at the multiple cloning site by 
insertion of a NcoI site was used for expression of the fragment number six E1F6 protein. 
 
pKFSC plasmid with backbone interdependentonpHEN4II phagemid vector containing SfiI-
BstEII, AscI-NotI cloning sites, and the 218* linker was used for expression of the scFv-FM3 
single chain. The pHEN4II vector is based on the pHEN4C vector. 
 
pKF-VLwas an intermediate vector derivating from pUC19 for heavy (VL) chain, contains 
blunt ended was created by KaspAI before adding the blunt end PCR products, and used for 
subcloning and expression of soluble scFv-FM3 fragments (Dr. Jörg Nähring, Fraunhofer 
IME, Aachen, Germany). 
 
pKF-VHwas an intermediate vector derivating from pUC19 for heavy (VH) chain, contains 
blunt ended was created by KaspAI before adding the blunt end PCR products, and used for 
subcloning and expression of soluble scFv-FM3 fragments (Dr. Jörg Nähring, Fraunhofer 
IME, Aachen, Germany). 
 
pTRA (Thomas Rademacher, Institut für Biology VII, RWTH Aachen, Germany) is an 
optimized plant expression vector containing the CaMV 35S expression cassette with a 
duplicated 35S enhancer region and the CaMV termination sequence preceeded by a 
polyadenylation site. The structure of the expression cassette was enhanced CaMV promotor-
CHS-signal peptide-gene and Pw CaMV termination sequence. 
II.1.7 Oligonucleotides 
Oligonucleotides used for sequence analysis and amplification of DNA are listed below. All 
oligonucleotides were synthesized by MWG (Ebersberg, Germany). 
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Table 3: Names and sequences of synthetic oligonucleotides used for cDNA synthesis and PCR 
amplification of whole E1 and E1 truncated fragments.  
 
Name Sequence Tm [°C] 
E1del 1 F 5-TGC CAT GGC TCC AAC TCA AGT ATT G-3 54.78 
E1del 1R 5- GCG GCC GCG GAG TGA GCG CTA CCC AG-3 73.43 
E1del 2 F 5-GGC CAT GGC CTA CCA AGT CG-3 62.59 
E1del 2 R 5-TCA TAC ACA ATA CTT GCG GCC GCA TAT-3 63.08 
E1del 3 F 5- AAC CAT GGT TCC TCC CGC TGC TG-3 53.26 
E1del 3 R 5- CTG TTG CGG CCG CAT TGT CGT AGT GGG-3 59.51 
E1del 4 R 5- GAT GGC GGC CGC AAC AGA CTG G-3 47.51 
E1del 4 F 5- CCC ATG GCA GGA ACA GCA GC-3 78.78 
E1del 5 F 5- ATC CAT GGG TAT GTG GGG GAT T-3 61.24 
E1del 5 R 5- GCT GAT ACA TGG CCG CGG CCG CCG AT-3 40.10 
E1del 6 F 5- CAG GAT CCA GAC TGC AAT TGC TCA A-3 61.20 
E1del 6 R 5- ACG AAT TCC AAT TCA TTA TC-3 64.89 
E1 F 5-TGC CAT GGC TCC AAC TCA AGT ATT G-3 65.72 
E1 R 5-GCG AAT TCG TGC GG CC GC GCAT-3 55.57 
The melting temperature (Tm) was calculated using the primer3 software 
(http://frodo.wi.mit.edu/) and refers to the hybridizing region and restriction sites  
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Table 4: Nucleotide sequences of PCR primers used for amplification of mouse antibody heavy chains 
cDNAs, the different 5’ primers are arranged in 8 groups 
 
Name MIX A Name MIX F 
Primer-VH-01 5 GAAGTGCAGCTGGTGGAGT Primer-VH-27 5  ´NAGGTCCAGCTGCAACAGT 
Primer-VH-02 5  ´GAAGTGCAGCTGGTGGAAT Primer-VH-28 5  ´NAGGTCCAGCTGCAGCAGT 
Primer-VH-03 5  ´GAAGTGAAGCTGGTGGAGT Primer-VH-29 5  ´NAGGTCCAGTTGCAACAGT 
Primer-VH-04 5  ´GAAGTGAAGCTGGTGGAAT Primer-VH-30 5  ´NAGGTCCAGTTGCAGCAGT 
Primer-VH-05 5  ´GAGGTGCAGCTGGTGGAGT Primer-VH-31 5  ´NAGATCCAGTTGGTGCAGT 
Primer-VH-06 5  ´GAGGTGCAGCTGGTGGAAT Primer-VH-32 5  ´NAGATCCAGCTGGTGCAGT 
Primer-VH-07 5  ´GAGGTGAAGCTGGTGGAGT Name MIX G 
Primer-VH-08 5  ´GAGGTGAAGCTGGTGGAAT Primer-VH-33 5  ´CAGGTTACTCTGAAAGAGT 
Name MIX B Primer-VH-34 5  ´CAGATTACTCTGAAAGAGT 
Primer-VH-09 5  ´NAGGTGCAGCTTGTAGAG Primer-VH-35 5  ´CAGGCTTATCTACAGCAGT 
Primer-VH-10 5  ´NAGGTTCAGCTGCAGCAGT Primer-VH-36 5  ´CAGGTTCACCTACAACAGT 
Name MIX C Primer-VH-37 5  ´CAGGTTCAGCTGCAACAGT 
Primer-VH-11 5  ´GAGGTGAAGCTTCTCGAGT Primer-VH-38 5  ´NAGGTTCAGCTCCAGCAGT 
Primer-VH-12 5  ´GAAGTGAAGCTTGAGGAGT Name MIX H 
Primer-VH-13 5  ´GATGTGAACCTGGAAGTGT Primer-VH-39 5  ´NAGGTTCAGCTGCAGCAGT 
Primer-VH-14 5  ´GAGGTGAAGCTGCATGAGA Primer-VH-40 5  ´NAGGTTCAACTGCAGCAGT 
Name MIX D Primer-VH-41 5  ´NAGGTCCAGCTGCAGCAGT 
Primer-VH-15 5  ´GATGTGCAGCTTCAGGAGT Primer-VH-42 5  ´NAGGTCCAACTGCAGCAGT 
Primer-VH-16 5  ´GATGTACAGCTTCAGGAGT Primer-VH-43 5  ´CAGGTCCAACTGCAGCAGC 
Primer-VH-17 5  ´GAGGTGCAGCTTCAGGAGT 
Primer-VH-18 5  ´CAGATGCAGCTTCAGGAGT 
Name MIX E 
Primer-VH-19 5  ´NAGGTCCAGCTGCAGCAGT 
Primer-VH-20 5  ´NAGGTCCAGCTGCAGGAGT 
Primer-VH-21 5  ´NAGGTCCAGCTGAAGCAGT 
Primer-VH-22 5  ´NAGGTCCAGCTGAAGGAGT 
Primer-VH-23 5  ´NAGGTGCAGCTGCAGCAGT 
Primer-VH-24 5  ´NAGGTGCAGCTGCAGGAGT 
Primer-VH-25 5  ´NAGGTGCAGCTGAAGCAGT 
Primer-VH-26 5  ´NAGGTGCAGCTGAAGGAGT 
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Table 5: Nucleotide sequences of PCR primers used for amplification of mouse antibody light chain 
cDNAs, the different 5’ primers are arranged in 8 groups 
Name MIX 1 Name MIX 5 
Primer-VL-01 5 GACATCCAGATGACTCAGTC Primer-VL-34 5  ´AGTATTGTGATGACCCAGAC 
Primer-VL-02 5  ´GACATCCAGATGATTCAGTC Primer-VL-35 5  ´GAAACAACTGTGACCCAGTC 
Primer-VL-03 5  ´GATGTCCAGATGATTCAGTC Primer-VL-36 5  ´ATCCACTGCAGATATTGTGA 
Primer-VL-04 5  ´GATATCCAGATGACACAGAC Primer-VL-37 5  ´ACTGGAGAAACAACACAGGC 
Primer-VL-05 5  ´GACATCCAGATGACACAGTC Primer-VL-38 5  ´GATGTCCAGATAACCCAGTC 
Primer-VL-06 5  ´GACATCCAGATGACACAATC Name MIX 6 
Primer-VL-07 5  ´GACATCCAGATGACCCAGTC Primer-VL-39 5  ´GACATTGTGCTGACACAGTC 
Primer-VL-08 5  ´GACATCCAGATGAACCAGTC Primer-VL-40 5  ´GACATTGTGCTAACACAGTC 
Primer-VL-09 5  ´GAAATCCAGATGACCCAGTC Primer-VL-41 5  ´GATATTGTGCTAACTCAGTC 
Primer-VL-10 5  ´GACATCAAGATGACCCAGTC Primer-VL-42 5  ´GACATTGTGCTCACCCAATC 
Primer-VL-11 5  ´GACATTCAGATGACCCAGTC Name MIX 7 
Primer-VL-12 5  ´GACATCCTGCTGACCCAGTC Primer-VL-43 5  ´GAAATTGTGCTCACTCAGTC 
Primer-VL-13 5  ´GACATCCTGATGACCCAATC Primer-VL-44 5  ´GAAAATGTGCTCACCCAGTC 
Primer-VL-14 5  ´GACATCTTGCTGACTCAGTC Primer-VL-45 5  ´GAAATTGTGTTGACCCAGTC 
Primer-VL-15 5  ´GACATTTTGATGACCCAGTC Primer-VL-46 5  ´GAAAATGTGCTGACCCAGTC 
Name MIX 2 Primer-VL-47 5  ´ GAAATTTTGCTCACCCAGTC 
Primer-VL-16 5  ´GACATTGTGATGACCCAGTC Primer-VL-48 5  ´GAAATTGTGCTCACCCAGTC 
Primer-VL-17 5  ´GACATTGTGATGACTCAGTC Name MIX 8 
Primer-VL-18 5  ´GACATTGTGATGACACAGTC Primer-VL-49 5  ´GAAAATGTTCTCACCCAGTC 
Primer-VL-19 5  ´GACATTGTGATGTCACAGTC Primer-VL-50 5  ´GAAATGGTTCTCACCCAGTC 
Name MIX 3 Primer-VL-51 5  ´CAAATTCTTCTCACCCAGTC 
Primer-VL-20 5  ´AACATTATGATGACACAGTC Primer-VL-52 5  ´CAAATTGTTCTCACCCAGTC 
Primer-VL-21 5  ´GACATTGTAATGACCCAATC Primer-VL-53 5  ´CAAATTGTTCTCTCCCAGTC 
Primer-VL-22 5  ´AACATTGTAATGACCCAATC Primer-VL-54 5  ´CAAATTGTTCTCACCCAGTC 
Primer-VL-23 5  ´AACATTGTGCTGACCCAATC 
Primer-VL-24 5  ´GACATTGTGCTGACCCAATC 
Name MIX 4 
Primer-VL-25 5  ´GATGTTGTGATGACCCAAAC 
Primer-VL-26 5  ´GATGCTGTGATGACCCAAAC 
Primer-VL-27 5  ´GATGTTTTGATGACCCAAAC 
Primer-VL-28 5  ´GATGTTGTGGTGACTCAAAC 
Primer-VL-29 5  ´GATGTTGTTCTGACCCAAAC 
Primer-VL-30 5  ´GATGTTGTGATGACCCAGAC 
Primer-VL-31 5  ´GATATTGTGATGACGCAGGC 
Primer-VL-32 5  ´GATATTGTGATGACTCAGGC 
Primer-VL-33 5  ´GATATTGTGATAACCCAGGA 
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Table 6: Primers used for DNA sequencing 
 
PUC19 Universe GTT GTA AAA CGA CGG CCA GT 
PUC19 Reverse ACA CAG GAA ACA GCT ATG AC 
pHEN forward GCC GCT GGA TTG TTA TTA CTC GC 
pHEN backward TTT CAA CAG TCT ATG CGG CCC C 
pSS 5 ATC CTT CGC AAG ACC CTT CCT CT 
pSS 3 AGA GAG AGA TAG ATT TGT AGA GA 
pGEX forward GGG CTG GCA AGC CAC GTT TGG TG 
pGEX backward TTT CAA CAG TCT ATG CGG CCC C 
 
 Primers used for PCR amplification of recombinant DNA from plant vector: 
forward pSS 5: 5 - GAC CCT TCC TCT ATA TAA GG (20-mer) 
  reverse pSS 3: 5 - C AC ACA TTA TTC TGG AGA AA (20-mer) 
II.1.8 Buffers, media and solutions 
All standard solutions, buffers, and media were prepared according to Sambrook et 
al.[106]Compositions of non-standard solutions or buffers are listed at the end of the 
respective method section. Media for cultivating bacteria were sterilized by autoclaving 
(121oC/1-2 bar), all other solutions were sterile filtered (0.2 m). Thermo labile components 
such as antibiotics were sterile filtered and added to the media after autoclaving and cooling 
to 50°C. 
II.1.9 Matrices and membranes 
Glutathione sepharose 4B from Amersham Pharmacia Biotech was used for purification of 
GST fusion proteins (II.2.2.2). Ni-NTA agarose matrix from Bio-RAD was used for 
purification of scFv-FM3 fragments from large scale cultures by immobilized metal ion 
affinity chromatography (IMAC) (II.2.2.3). ImmobilonTM-P transfer membrane (PVDF) 
(0.45m) from Millipore, HybondTM-C nitrocellulose membrane (0.45m) from Amersham 
Life Science and Whatman no.1 paper from Whatman (Maidstone, England) were used in 
immunoblot analysis (II.2.3.3). PD10 - desalting columns (Amersham Biosciences, 
Buckinghamshire). 
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II.1.10 Equipment and applications 
Centrifuges: AvantiTM 30 and AvantiTMJ-25 (Beckman, California, USA), Biofuge A 
(Heraeus, Hanau), Sigma 3-10 and Sigma 4-10 (Sigma, St. Louis, Missouri, USA), RC5C and 
RC5B plus (Sorval instruments, Du Pont, Bad Homburg). Rotors: F0650, F2402H, JLA 
10.500 and JA 25.50 (Beckman), #1140 and #11222 (Sigma), RLA-300, SS-34 and GS-3 (Du 
Pont). 
Chromatography equipment: ÄKTA explorer 10xT (Amersham Pharmacia Biotech), gel 
filtration XK26 column 26 mm inside diameter, 20 cm length (Amersham Pharmacia 
Biotech), 150 ml super-loop (Amersham Pharmacia Biotech) and UNICORN control, 
evaluation and documentation software (Amersham Pharmacia Biotech). 
DNA gel electrophoresis apparatus: Wide mini and mini cells for DNA agarose 
electrophoresis and power supplies (Bio-Rad). 
Electroporation apparatus: “Gene pulserTM”, “Pulse controller” unit, Extender unit 
(BioRad) and 0.2 cm or 0.4 cm cuvettes (Bio-Rad). 
Innova
TM 
4340 incubator shaker (New Brunswick Scientific, Nürtingen). 
Innova
TM
 4340 incubator shaker (New Brunswick Scientific, Nürtingen). 
PCR Thermocyclers: Primus and Primus 96 plus (MWG-Biotech). 
Photometers: Spectrophotometer Uvikon 930 Fluka (Neu-Ulm), and multi-channel 
spectrophotometer Spectromax 340 (Molecular Devices, Sunnyvale, Kalifornien). 
Protein gel electrophoresis equipment: Mini PROTEAN IITM from BioRad. Gel Air Dryer 
(Bio-Rad). 
UV-Transilluminators: Wavelength 302 nm and UVT-20M (Herolab). UV-chamber (Bio-
Rad). 
Software: Windows XP operating system (Microsoft); Microsoft Office 2007 (Microsoft); 
Adobe Photoshop 9.0 (Adobe); Origin 8.0 (Data analysis and technical graphics, Microcal 
Software, Inc.); (Wisconsin Package TM of Genetic Computer Group), Chromas pro 
software. 
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II.2 Methods 
All experiments related to the genetic engineering were performed according to the 
regulations of “S1-Richtlinien” and were officially approved by the “Regierungspräsidium 
des Landes NRW” (RP-Nr.: 23.203.2 AC 12, 21/95) and “BGA” [AZ 521-K-1-8/98:AI3-
04/1/0866/88 (S1) and 55.8867/-4/93 (greenhouse)]. General recombinant DNA techniques, 
i.e. DNA extraction, DNA precipitation, restriction enzyme digestion, DNA ligation, DNA 
agarose gel electrophoresis, were according to the standard protocols described in Sambrook 
et al. [106]. 
 
II.2.1 Recombinant DNA technologies 
II.2.1.1    Competent cells for RbCl-mediated transformation 
E. coli strain DH5 competent cells were prepared for RbCl-mediated transformation by heat-
shock as described by Hanahan [107]. A single bacterial colony was inoculated in 5 ml of LB 
broth and cultured at 37°C overnight (o/n). 0.5 ml of the o/n culture was transferred into 50 
ml of LB broth containing 20 mM MgSO4 and 10 mM KCl. The cells were cultured at 37°C 
for 3-4 hours until the OD600nm reached 0.4-0.5 and then transferred to an ice-cold tube. After 
store on ice for 10 min, the cells were recovered by centrifugation (2000 g/4°C/10 min). The 
pellets were resuspended in 15 ml ice-cold TfB-I solution by gentle vortexing and stored on 
ice for 10 min. The cells were recovered by centrifugation as described above and 
resuspended in 2 ml ice-cold TfB-II. 200 l-aliquots of the suspension were dispensed into 
prechilled microcentrifugation tubes, frozen immediately in liquid nitrogen and stored at 
-80°C. 
TfB-I pH 5.8: 
 Potassium acetate 30 mM 
 MnCl2 50 mM 
 CaCl2 10 mM 
 Glycerol 15% (v/v) 
TfB-II pH 6.8: 
 MOPS 30 mM 
 CaCl2 75 mM 
 RbCl 10 mM 
 Glycerol 15% (v/v) 
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II.2.1.2  Transformation of E. coli by heat-shock 
As soon as the competent cells (II.2.1.1) were thawed, plasmid DNA (up to 100 ng) 
(II.2.1.10) or ligation products were mixed gently with the competent cells and placed on ice 
for 30 min. The cells were then exposed to 42°C for 90 seconds and placed on ice for 2 min. 
800 l of LB medium were added to the tubes and incubated at 37°C for 45 min. 200 l of 
cells were plated onto a LB-agar plate supplemented with appropriate antibiotics and 
incubated at 37°C overnight. 
II.2.1.3 Preparation of electrocompetent E. coli 
Electrocompetent E. coli were prepared from the following strains; DH5, BL21 (DE3), 
andXL1-blue as described by Dower et al.[108]. A single bacterial colony from an LB plate 
was inoculated in 5 ml LB-broth and cultured at 37°C o/n. Three ml of fresh o/n culture was 
transferred into 500 ml of LB broth. The cells were cultured at 37°C for 3-4 hours until the 
mid-log phase (OD600nm = 0.5-0.8). Then the cells were placed on ice for 15-20 min and 
harvested by centrifugation (3000 g/4°C/10 min). Cells were washed three times with sterile 
water and resuspended in ice-cold 10% (v/v) glycerol to a 300-fold concentration from the 
original culture volume (at >1010 cells/ml). 40 l aliquots were stored at -80°C. 
II.2.1.4 Transformation of E. coli by electroporation 
Electrocompetent cells (II.2.1.3) were thawed on ice and mixed with 1 pg to 300 ng of DNA 
in sterile dH2O. The cell/DNA mixture was transferred into a prechilled electroporation 
cuvette (0.2 cm) and assembled into a safety chamber. After application of the pulse (25 F, 
2.5 kV, 200 ), the cells were diluted in 1 ml of SOC medium and incubated at 37°C with 
shaking for 1 h. Finally, 100 l of the cells were plated onto LB-agar containing appropriate 
antibiotics and incubated at 37°C o/n. 
II.2.1.5 Preparation of electrocompetent Agrobacterium cells 
A single colony of Agrobacterium tumefaciens strain GV3101 grown on YEB-agar plate 
containing 100 g/ml rifampicin (Rif) and 25 g/ml kanamycin (Km) (YEB-Rif-Km) was 
inoculated in 5 ml of YEB-Rif-Km medium in a 100 ml Erlenmeyer flask and incubated at 
28°C for two days with shaking (250 rpm). One ml of the culture was transferred into 100 ml 
of YEB-Rif-Km medium and cultivated at 28°C for 15-20 h with shaking (250 rpm) until the 
OD600nm reached 1-1.5. The cells were chilled on ice for 15 min and spun down by 
centrifugation (4,000g/4°C/5 min). The culture medium was decanted and the cells were 
washed three times with 10 ml of dH2O by centrifugation and resuspended in 500 l of sterile 
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10% (v/v) glycerol. 45 l-aliquots of the suspension were dispensed into prechilled 
microcentrifugation tubes, frozen immediately in liquid nitrogen and stored at -80°C. 
 
YEB-Rif-Km medium: 
 Nutrient Broth 0.5% (w/v) 
 Yeast Extract 0.1% (w/v) 
 Peptone 0.5% (w/v) 
 Sucrose 0.5% (w/v) 
2 mM MgSO4, 100 g/ml rifampicin, 25 g/ml kanamycin were added after autoclaving and 
cooling. 
II.2.1.6 Transformation of Agrobacterium by electroporation 
0.2-1.0 g of plasmid DNA (II.2.1.10) in sterile dH2O was added to a thawed aliquot of 
electrocompetent Agrobacterium cells (II.2.1.5) and placed on ice for 3 min. The cell/DNA 
mixture was transferred into a prechilled electroporation cuvette (0.2 cm) and assembled into 
a safety chamber. After application of the pulse (25 F, 2.5 kV, 200 ), the cells were diluted 
in 1 ml of SOC medium in a 4 ml tube and incubated at 28°C with shaking (250 rpm) for 1 h. 
Finally, 1-10 l of the cells were plated on YEB-agar containing 100 g/ml rifampicin (Rif), 
25 g/ml kanamycin (Km) and 100 g/ml carbenicillin (Carb) (YEB-Rif-Km-Carb) and 
incubated at 28°C for 2-3 days. As a control transformation of Agrobacterium cells with H2O 
was performed. 
II.2.1.7 Determination of the efficiency of recombinant bacteria transformation 
Efficiency of transformation of each new batch of competent cells was measured by test 
transformations with known concentrations of super coiled plasmid pUC18 for E. coli. The 
following transformation rates were obtained; RbCl 107/g pUC18, electrocompetent E. 
coli108/g pUC18. 
II.2.1.8 Culturing of E. coli and glycerol stock preparation 
Individual colonies of all strains were obtained by plating the pertaining strain on LB agar 
plates. Incubation was performed at 37oC. The plates were stored at 4oC for short periods (less 
than 2 weeks). LB medium containing the suitable antibiotics and 2% (w/v) glucose was 
inoculated with a single recombinant colony of E. coli and grown o/n at 37C with vigorous 
shaking (225 rpm). Glycerol stocks were prepared by mixing 600 l of a fresh overnight 
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culture with 600 l of 40% (w/v) sterile glycerol. Bacteria glycerol stocks were stored at -
80C. 
II.2.1.9   Growth of recombinant A. tumefaciens and preparation of glycerol 
stocks 
Single colonies of A. tumefaciens were examined for the presence of plasmids by control PCR 
(II.2.1.13). Positive colonies were inoculated in 10 ml of YEB-Rif-Km-Carb medium and 
cultivated at 28°C for 2-3 days with vigorous shaking at 250 rpm. The culture was transferred 
to Falcon tubes and Agrobacteria cells were pellet by centrifugation at 4000g for 10 min at 
15°C. The cells were resuspended in a 1:1 volume of YEB Rif-Km-Carb medium and 
glycerol stock media (GSM). The suspension was aliquoted (100 l) and stored at -80°C for 
further experiments. 
 
Glycerol stock media (GSM): 
  Glycerol 50% (v/v) 
  MgSO4 100 mM 
  Tris, pH 7.4 25 mM 
II.2.1.10   Isolation of plasmid-DNA from E.coli 
Recombinant plasmid DNA was purified with the Qiagen plasmid DNA Mini-and Midi- prep 
kits according to the manufacturer‟s instructions based on the alkaline lysis method described 
by Sambrook et al [106]. Ethidium bromide was added to the gel solution and TBE 
electrophoreses running buffer prior to the experiment. Known amounts of DNA molecular 
markers such as 1 Kb ladder, 100 bp ladder and -digested with PstI were used for evaluation 
and determination of DNA concentration and size. The DNA bands were visualised directly 
upon illumination with a UV transilluminator at 302 nm.  
II.2.1.11   Preparative agarose gel electrophoresis 
Preparative gel electrophoresis was used for large scale purification of a particular DNA 
fragment (II.2.1.10) from a mixture of DNA fragments after restriction enzyme digestion 
(II.2.1.17). The agarose containing the DNA fragment of interest was excised from the gel on 
an UV transilluminator with a sterile scalpel. The DNA extraction was performed with 
QIAquick Gel extraction kit according to the manufacturer‟s guidelines. The concentration of 
recovered DNA was measured by spectrophotometer or determined by agarose gel 
electrophoresis (II.2.1.11) and was used in further experiments. 
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II.2.1.12   PCR amplification 
Polymerase chain reaction (PCR) was used for amplification of HCV-E1 gene from pMS L 
GFP vector (Gen-bank accession number M16650) using synthetic oligonucleotides based on 
the complete E1 sequence of genotype 1b sequence, and the six truncated fragments (E1-F1 to 
E1-F6) (II.2.1.13). DNA was amplified, based on the protocol of Sambrook et al. with Taq- or 
high fidelity DNA-polymerase and DNA polymerase buffer from Roche. The reactions were 
performed in 0.2 ml PCR reaction tubes (Biozym Diagnostik GmbH, Hessisch Oldendorf), 
using a DNA thermal Cycler (MWG). The cycler contained a heated lid to avoid the use of 
mineral oil. For rapid identification of recombinant E. coli and Agrobacteria control-PCR was 
carried out to detect plasmids as described by Jesnowski et al. [109]. The optimal annealing 
temperature (TM) of the primers was experimentally optimised or calculated based on the 
empiric formula: TM = {22 + 1, 46 [2* (G + C) + (A + T)]} 
The annealing temperature and the time for denaturation were changed according to the TM 
value of primers and the length of the target gene. 
The performance of each PCR reaction was checked by running 5 l of each reaction on 
agarose gels, with appropriate DNA markers (II.2.1.11). 
Table 7: PCR reactions were carried out in a total volume of 50 l as described below: 
Components Volume Final concentration 
10X PCR buffer 5 l 1X 
50 mM MgCl2 1.5 l 1.5 mM 
10 mM dNTPs 1 l 0.2 mM each 
10 pmol forward Primer 0.5-1 l 10 pmol 
10 pmol backward primer 0.5-1 l 10 pmol 
Template DNA 0.5-5 l 10-100 ng 
Taq DNA polymerase (5U/l) 0.25 l 1.25 units 
dd H2O to 50 l  
 
Amplification was carried out under the following conditions: 
    5 min 95C 
    0.5 min 94C 
    0.5 min 55C          x 20-35 
    1 min 72C 
5 min 72C  
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II.2.1.13   PCR based analysis of recombinant bacterial clones 
Bacterial clones (II.1.4) harbouring plasmids containing the gene of interest were identified 
by PCR as described by Jesnowski et al., Single colonies were picked with sterile toothpicks. 
The bacteria laden toothpick was first used for inoculating a ”master plate” and then dipped in 
a PCR tube containing 10 µl of sterile water. 15 µl of the PCR mix (II.2.2.8.1) was added to 
the 10 µl bacterial suspensions to give a final reaction volume of 25 µl. Specific primers 
annealing to the 5´ and 3´ ends of the cloned gene or primers specific for the vector backbone 
were used for PCR amplification reaction (II.2.1.13). The reaction conditions for the PCR 
were the same, except that the time for initial denaturation of DNA was increased to 
10 minutes. 10 µl of the PCR product was analysed on a 1.2% (w/v) agarose gel (II.2.1.11).  
II.2.1.14   PCR amplification of variable domains of mouse mAbs 
The antibody heavy chain variable domains were amplified with a set of 8 different mixes of 
primers (Table -3) and a mixture of primers for antibody light chains (Table 4). PCR reactions 
were carried out in a total volume of 50 l to which 10 pmol of each primer and one-fifth of 
the first strand cDNA reaction product (II.2.5.2) was added. Reaction conditions: an initial 
denaturation for 5 min at 94°C followed by 30 cycles at 94°C for 1 min, 55°C for variable light 
chain /53°C for variable heavy chain for 1 min, 72°C for 2 min and a final extension at 72°C for 
10 min. 10 µl of the PCR product was analysed on a 1.2% (w/v) agarose gel (II.2.1.11). 
II.2.1.15    DNA sequencing 
pET26b(+) forward and pET26b+ backward primers were used for sequencing the E1 gene 
and E1-F1 to E1-F5 truncated fragments cloned in the pET26b+ vector. pGEX forward and 
pGEX backward primers were used for sequencing the E1-F6 truncated fragment cloned in 
the pGEX-5X-3 vector. Forward and backward pHEN primers were used for sequencing of 
scFv-FM3 fragment in the pKFsc phagemid vector. Universal and reverse primers were 
employed for sequencing of antibody heavy and light chain fragments cloned in pKFVH and 
pKFVL vectors respectively. pSS 5‟ and pSS 3‟ primers were used for sequence analysis the 
target genes in pTRA vector. Chromas pro software package was used for displaying the 
chromatogram files after DNA sequencing and the sequences were edited and exported for 
further analysis. 
II.2.1.16      Restriction endonuclease digests of DNA 
As all restriction enzymes were supplied by NEB, restriction digests were done according to 
the manufacturer's recommendations using enzyme amounts between 1 and 20 U, depending 
on the amount of DNA used. For double digests the NEB web page was consulted. 
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In case a vector backbone fragment was generated by restriction with a single enzyme, the 
fragment was dephosphorylated following the restriction endonuclease digest by adding 1 µl 
CIP (NEB) and 1 h incubation at 37°C. For test restrictions of newly cloned constructs the 
restriction enzymes were chosen so, that it was possible to distinguish the new vector from the 
original vector by the band pattern. 
II.2.1.17    Ligation of DNA fragments 
The ligation of DNA fragments was performed with the Quick Ligation Kit (NEB) according 
to the manufacturer's instructions. 
II.2.2   Expression and purification of recombinant proteins 
II.2.2.1 Bacterial expression and purification of full size of E1 and E1 truncated 
proteins 
BL21 (DE3) carrying pET26b+ plasmid with the full size E1, or E1 truncated fragments 
(E1F1-E1F5) genes were grown in 10 ml of LB medium at 37°C containing 100 g/ml 
ampicillin (LBA). The following day, the non-induced o/n culture was diluted 1:60 with fresh 
LBA medium and grown at 37°C with vigorous shaking until OD600 reached 0.6. IPTG at a 
final concentration of 1 mM was added and the culture was grown at 37°C for 4 hours. The 
cells were harvested by centrifugation at 4000 g for 15 min at 4°C. E1 proteins were purified 
from inclusion bodies via C-terminal his6 tag using Ni-NTA affinity chromatography under 
denaturating conditions as described below. The bacterial pellet was resuspended in lysis 
buffer B containing 8 M urea and incubated for 1 h at room temperature. After centrifugation 
at 10,000 g for 30 min, the supernatant was loaded onto pre-equilibrated Ni-NTA column and 
passed through the columns twice. After several washing steps with washing buffer C, the 
bound protein was eluted twice with 300 l of elution buffer E, and stored in 8 M urea. 
Fractions were collected and analysed by SDS-PAGE (II.2.3.2) and stored at -20°C for further 
experiments. 
Lysis buffer B:  8 M urea; 0.1 M NaH2PO4; 0.01 M Tris HCl pH 8.0 
Washing buffer C:  8 M urea; 0.1 M NaH2PO4; 0.01 M Tris HCl pH 6.3 
Elution buffer E:  8 M urea; 0.1 M NaH2PO4; 0.01 M Tris HCl pH 4.5 
II.2.2.2 Bacterial expression of GST E1F6 fusion proteins  
GST and GST-fusion proteins were expressed and purified according to a modified protocol 
based on Smith et al. [110]. A freshly transformed single colony of E. coli strain BL21(DE3) 
(Novagen) harbouring the recombinant plasmid DNA was inoculated in 10 ml of 2YT 
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medium containing 1% (w/v) glucose and 100 g/ml ampicillin and cultivated o/n at 37°C 
with vigorous shaking. The following day 400 ml of fresh 2YT/0.1% (w/v) glucose medium 
inoculated with 3 ml overnight culture and grown at 30°C and 225 rpm to an OD600 nm of 0.8-
1. Expression of recombinant proteins was then induced by addition of IPTG to a final 
concentration of 0.1 mM. Cells were cultured o/n at 18°C. The cells were harvested by 
centrifugation 7700 g for 10 min at 4°C and the supernatant discarded. The pellet was dried, 
resuspended in cold PBS buffer (20 ml/400 ml bacterial culture) and sonicated on ice 4 times 
for 40 sec (150 W with 30 sec intervals). Triton X-100 (20% (v/v) stock solution) was added 
to 1% final concentration. The cell lysate was incubated for 30 min at 4°C on a rotary shaker. 
Cell debris and insoluble components were removed by centrifugation 15000 g for 20 min at 
4°C and the supernatant subjected to glutathione affinity chromatography according to the 
manufacturer‟s instructions. 
II.2.2.3 Small scale bacterial expression of scFv-FM3 and purification of soluble  
fragments by IMAC 
For small scale expression scFv-FM3 cDNA was subcloned into the prokaryotic expression 
vector pKFsc using either NcoI/NotI restriction sites. Recombinant pKFsc plasmid was 
transformed into E. coli strain HB2151. A single recombinant colony was inoculated in 10 ml 
of 2YT medium containing 1% (w/v) glucose and 100 g/ml ampicillin and cultivated at 
37°C with shaking (200 rpm). Three ml of the o/n culture were transferred into 500 ml of 2YT 
media containing 0.1% (w/v) glucose and 100 g/ml ampicillin and grown at 37°C until the 
OD600 nm reached 0.7-0.8. Expression of the scFv-FM3 fragment was induced by addition of 
IPTG to a final concentration of 1 mM for 3 hours at 30°C. The culture was centrifuged 
(4000 g/4°C/20 min) and the pelleted bacteria were resuspended in 10 ml of resuspension 
buffer (30 mM Tris, 20 % (w/v) sucrose, pH 8.0). EDTA was added to a final concentration of 
1 mM. The suspension was incubated at 4°C for 10 min with gentle agitation followed by 
centrifugation at (8000 g/4°C/20 min). The supernatant S1 was removed and kept on ice. The 
pellet was resuspended in 9 ml of cold 5 mM MgSO4 and incubated at 4°C for 8-9 min on a 
rotatory shaker. EDTA was added to a final concentration of 1 mM and the suspension was 
agitated for 3 more minutes followed by centrifugation at (8000 g/4°C/20 min). The 
supernatant (S2) was mixed with the first supernatant (S1) and dialysed against PBS prior to 
IMAC affinity purification. Ni-NTA-agarose was added in a disposable column and 
equilibrated with 10-20 volumes of wash buffer. Imidazol and sodium chloride were added 
into the dialyzed periplasmic fraction to a final concentration of 10 mM and 500 mM, 
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respectively. The sample was passed twice through the pre-equilibrated Ni-NTA matrix. The 
column was washed with 20 volumes of wash buffer and the proteins were eluted in three 
fractions with 700 l of elution buffer. Collected fractions were immediately dialysed against 
PBS (pH 7.4) to remove imidazol and salt. To control the yield and purity of dialyzed scFv-
FM3 fragments 5 l were run in a SDS-PAGE (II.2.3.2). The concentration was determined 
using the Pierce BCA protein assay (II.2.3.1). 
Wash buffer: 1x PBS, 10 mM imidazol; 500 mM NaCl 
Elution buffer: 1x PBS, 250 mM imidazol pH 4.5 
II.2.3 Protein analysis 
II.2.3.1 Quantification of proteins 
The concentration of purified protein (II.2.3.4) was determined by Bradford [111]. or BCA 
(Pierce) assays. For Bradford assay the protein solution of interest was serially diluted. BSA 
was also serially diluted and used as standard. Ten l of each dilution was transferred into the 
wells of a low binding microtiter plate (Greiner, Solingen, Germany). Ten l of the buffer was 
used as a blank. 200 l of bradford reagent were added to each well, mixed with the proteins 
and incubated at RT for 10 min followed by the measurement of OD595nm. For each 
dilution, measurements were performed in triplicate and the average was taken for the 
calculation of the protein concentration. The Pierce BCA protein assay is a detergent-
compatible formulation based on bicinchoninic acid (BCA) for the colorimetric detection and 
quantification of proteins. This method combines reduction of Cu+2 to Cu+1 by proteins in an 
alkaline medium with the sensitive and selective colorimetric detection of the cuprous cation 
(Cu+1) using bicinchoninic acid. Concentration measurements were done according to the 
manufacturer‟s instructions, using BSA as standard. 
II.2.3.2 SDS-PAGE and Coomassie brilliant blue staining 
Discontinuous SDS-polyacrylamide gels (for the stacking gel: T = 4%, C = 2.6%, pH 6.8; for 
the separating gel: T = 12%, C = 2.6%, pH 8.8), were used for separation of protein samples. 
Before loading onto the gel, protein samples were denaturated in the presence of SDS and β-
mercaptoethanol. The proteins were separated electrophoretically with 20V/cm for 1 hour. 
Protein bands were revealed by staining with Coomassie brilliant blue or transfer to 
nitrocellulose membrane for immuneblot analysis. Proteins were detected after incubating the 
gel for 30 min in Coomassie staining solution at RT under constant rocking. Coomassie 
staining was removed by destaining solution until the protein bands was clearly visible. 
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SDS-PAGE running buffer (pH 8.3): 
 Tris 125 mM  
 Glycine 960 mM  
 SDS 0.5% (w/v) 
Coomassie staining solution: 
 Coomassie brilliant blue G-250 0.25% (w/v) 
 Methanol 50% (v/v) 
 Glacial acetic acid 9% (v/v) 
Coomassie destaining solution: 
 Methanol 10% (v/v) 
 Glacial acetic acid 10% (v/v) 
II.2.3.3 Immunoblot analysis 
Separated proteins (II.2.3.2) were transferred from an SDS-PAA gel to PVDF or HybondTM-C 
nitrocellulose membrane (0.45 m). After blotting the membrane was blocked with PBS 
buffer containing 3% (w/v) skim milk powder (MPBS). As primary antibody either anti c-
myc or anti his6 antibody was used in a dilution of 1:5000 in 1xPBS. Attachment of the 
primary antibody was detected by addition of the secondary polyclonal antibody coupled to 
alkaline phosphatase (AP). Both, primary and secondary antibodies were diluted in blocking 
buffer. The target protein was finally revealed by addition of substrate BCIP/NBT. 
PBS buffer (pH 7.3):  
 NaCl  137 mM 
 KCl  2.7 mM 
 Na2HPO4x2H2O 8.1 mM 
 KH2PO4 1.5 mM 
Transfer buffer (pH 8.3): 
 Tris-HCl, pH 8.3 25 mM 
 Glycine 92 mM 
 Methanol 20% (v/v) 
AP buffer (pH 9.6): 
 Tris-HCl, pH 9.6 100 mM 
 NaCl  100 mM 
 MgCl2  5 mM 
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II.2.3.4 Concentration and dialysis of proteins 
To desalt, concentrate or rebuffer protein samples with a volume of less than 1 ml, Nanosep 
10k Omega micro-concentrator tubes (Pall Life Sciences, East Hills, NY) were used 
following the manufacturers‟ instructions. For larger volumes (1-7 ml), PD10-desalting 
columns were used as described in the manufacturers‟ protocol. Volumes above 7 ml were 
dialysed with dialysis-tubes (Serva dialysis tubing, Serva, Heidelberg) with a cut-off of 6-8 
kDa at 4°C overnight against a 1000x volume of required buffer. Desalting was carried out in 
order to remove imidazol in the elution buffer of Ni-NTA or to change buffer system of 
purified protein for lyophilisation. 
 
II.2.3.5 ELISA (Enzyme-linked immunosorbent assay) 
Indirect ELISA was used for analysis of bacterially and plant expressed soluble E1 protein, 
about 10-50 μg/ml E1 mouse monoclonal antibodies in PBS were directly coated on high-
binding microtiter plates (M129B, Greiner) by incubation at 4°C overnight followed by a 
blocking step using 2% (w/v) skimmed milk in PBS. 50 μg/ml of bacterial produced E1 
protein in PBS was applied to the plates and incubated at 37°C for 2 h. Bound E1 were 
detected using 1:4000 diluted E1-specific monoclonal antibody conjugated with horseradish 
peroxidase (HRP), followed by ABTS substrate dissolved in ABTS buffer (Boehringer 
Mannheim) for color development at 37°C for 30 min, followed by the measurement of 
OD405 nm. Direct ELISA was used for analysis of bacterially and plant expressed soluble 
scFv-FM3 protein. About 10-50 μg/ml E1 antigen in PBS were directly coated on high-
binding microtiter plates by incubating at 4°C overnight followed by a blocking step using 2% 
(w/v) skimmed milk in PBS. 50 μg/ml of scFv-FM3 solution was applied to the plates and 
incubated at 37°C for 2 h. Bound scFvs were detected using 1:5000 diluted anti-c-myc 
monoclonal antibody followed by 1:5000 diluted horseradish peroxidase (HRP)-conjugated 
goat anti mouse polyclonal antibodies. ABTS substrate dissolved in ABTS buffer (Boehringer 
Mannheim) was used for color development at 37°C for 30 min followed by the measurement 
of OD 405nm. Sandwich ELISA (s-ELISA) was used for detection of HCV in infected 
patient‟s serum. This ELISA is based on monoclonal antibodies which react with E1 antigen. 
The mouse monoclonal antibodies (IgG) non-labeled were used on high binding plates for 
coating. Then the infected serum with HCV was applied, and the other monoclonal antibody 
HRP-labeled used as secondary mouse specific antibody to E1 antigen was used Table 8. 
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Table 8: Parameter for the detection of recombinant E1 in sandwich ELISA 
Step Volume/well concentration incubation 
1st E1-mAbs 50 ng 1:20 in coating buffer 2 h at RT 
Blocking 200 μl 2% (w/v) BSA in PBS 0.5 h at RT 
Antigen 50 ng in PBS 1 h. at RT 
2st E1-mAb-HPR 50 ng in PBS 1-2 h at RT 
ABTS 100 μl 0,953 mg/mL SP 15-30 min. at RT 
In between the different steps the plate was washed 3 times with PBST, followed by measurement 
of the OD at 405 nm. 
 
II.2.4  Monoclonal antibody production 
II.2.4.1 Immunization of mice 
Three female mice (Balb/c) were immunized with 50 g of E1 protein mixed with 40 µl 
GEBRU‟s adjuvant. Two further injections into the tail vein were given at biweekly intervals 
with the same amount of antigen and 20µl GEBRU‟s adjuvant per mouse. The final boost was 
performed 4 days prior to sacrifice. After the last boost, blood was taken from the tail vein 
using a 26 gauge needle (1-2 l) and a capillary for picking up blood. The blood was diluted 
1000-fold with PBS for estimation of antibody titers. 
II.2.4.2 Determination of antisera titers by ELISA 
The determination of polyclonal antibody titers from sera of mice was performed by direct 
ELISAs (II.2.3.5) using E1 recombinant protein as antigen. To determine the titer of E1-
specific antibodies, 100 ng/well of recombinant E1 were coated on ELISA plates and GST 
protein (10 g/ml) was used as control. Antigens were coated at 37oC for 2 h and blocked 
with 1% (w/v) BSA in 1x PBS. Serial dilutions of sera (1:500- 1:256,000) in blocking buffer 
were added to the coated plates and incubated at 37°C for 1.5 h. After three washes with 
PBST bound antibodies were detected by addition of 1:5,000 diluted AP-labeled goat anti-
mouse polyclonal antibodies in blocking buffer and p-nitrophenyl phosphate (pNPP) as 
substrate (Sigma). ELISA plates were incubated at 37°C for 1 h followed by measurement of 
the OD405 nm. 
II.2.4.3 Subcloning of hybridoma clones by limiting dilution 
The hybridoma clones (II.2.4.3) were grown in RPMI medium supplemented with10% (v/v) 
fetal calf serum (FCS) at 37°C in a humidified 5% CO2 incubator. Subcloning of hybridoma 
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was performed by limiting dilution. The hybridoma cells were diluted at a ratio of 
100 cells/10 ml medium and 100 µl per well of the diluted cell suspension was aliquoted in a 
96 well tissue culture plate. Wells with single colonies were identified and the secretions of 
mouse mAbs were confirmed by direct E1 antigen ELISA (II.2.3.5).  
 
II.2.4.4 Isotype determination of generated E1-specific monoclonal antibodies 
The isotype determinations of selected mAbs were performed by ELISA (II.2.3.5) using a 
commercially available (BD isotyping kit) following the manufacturer‟s protocol 
(Biosciences). Fifty μl of each purified isotype-specific rat-anti-mouse monoclonal antibody, 
diluted 1:50 in coating buffer (1x PBS), were added to the wells of a high binding microtiter 
plate. The plate was covered and incubated for 1 h at 37°C. The wells were carefully washed 
with 1x PBST and remaining free binding sites were blocked with 200 μl 1% (w/v) BSA for 1 
h at RT. One hundred μl of each hybridoma cell culture supernatant were pipetted to the wells 
of the prepared microtiter plate and samples were incubated for 1 h at RT. A positive 
reference antigen mixture provided in the kit was used as control. Wells in which hybridoma 
cell culture supernatant was replaced by 1x PBS were included as negative control. The plate 
was washed thoroughly 6 times with 1x PBST, soaking the wells each time for 1 min. HRP-
labeled rat anti-mouse IgG solution (100 μl) diluted 1:100 in 1% (w/v) BSA were added and 
incubated for 1 h at RT. One hundred μl substrate solution, prepared by mixing equal volumes 
of reagent A and reagent B (both provided in the kit), were added to each well and incubated 
for 3-10 min at RT. When reactions developed a greenish-blue color, the reaction was stopped 
with 50 μl stop solution provided in the kit. The plates were immediately measured in an 
ELISA reader at OD405 nm. 
II.2.4.5 Purification of mouse mAbs from the hybridoma supernatant 
The hybridoma cells were grown in 500 ml culture flasks. The culture supernatant was 
harvested when the medium became acidic. The storage bottle for collection of the cell 
supernatant was always handled in sterile conditions to avoid any contamination. The mouse 
mAbs were purified from the hybridoma supernatant via protein G chromatography. One ml 
of protein G matrix was packed in a column and equilibrated with 5 column volumes (CV) of 
PBS (pH7.4). The hybridoma supernatant was centrifuged (10.000 g/4°C/10 min) then filtered 
through Whatman 3M paper before applying it onto the column. The supernatant was passed 
through the column at a flow rate of one ml/min. Non-specifically bound proteins were 
washed away with PBS containing 100 mM NaCl (pH 7.4) till the online UV detector showed 
zero absorbance at 280nm. The bound antibody was eluted from the column with 4 ml of 
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elution buffer (100 mM glycine, pH 3) under gravity flow. The pH of the eluate was 
immediately equilibrated to pH 7 by adding unbuffered 1 M Tris pH 11. 0.01% (w/v) of 
sodium azid and 10 % (v/v) glycerol were added to the eluate. The eluate was aliquoted and 
frozen at -20°C. The protein G matrix was regenerated by washing the column with 2 column 
volumes of 1.5 M HCl and stored in 20% (v/v) ethanol at 4°C. 1-10 microlitres of the eluate 
were used for ELISA (II.2.3.5), Western blot (II.2.3.3) and SDS-PAGE analysis (II.2.3.2). 
 
II.2.4.6 Preparation of antibody-HPR conjugate 
HCV-E1 antigen was detected by sandwich ELISA (II.2.3.5). FM1, FM3 and FM4 
monoclonal antibodies labeled with HRP according to the manual of the HRP Labeling Kit 
(Horseradish peroxidase (HRP) conjugation kit. Thermo Scientific). Briefly, antibody was 
dialyzed against 0.1 mol/L NaHCO3 (pH 9.5), concentrated to 2 g/L, and coupled to active 
HRP for 3 h at room temperature. The remaining HRP was blocked with 1 mol/L l-lysine. The 
labeled antibody was dialyzed against PBS (II.2.3.4), and preserved with the reagent provided 
in the HRP Labeling Kit. 
 
II.2.5 Construction of scFv-FM3 
II.2.5.1 Isolation of total RNA from spleen cells 
Spleens from immunized mice (II.2.4.1) were removed and dissected. Spleenocytes were 
prepared by disrupting the spleens through a meshing net and washed twice with RPMI 1640 
solution. The cells were homogenized in 1x PBS, aliquoted to not more than 1x108 cells and 
subjected to total RNA isolation using the „RNeasy Midi kit‟ followed by a TRIZOL 
extraction (GibcoBRL) to obtain high RNA yield. 
II.2.5.2 First strand cDNA synthesis 
To remove genomic DNA, about 3 μg total RNA was treated with DNase I enzyme 
(Fermentas). First-strand cDNA was synthesized from 5 g of total RNA using Super 
Script™ II Reverse Transcriptase (RT) (Invitogen) and oligo dT primer according to the 
manufacturer‟s instructions. 
II.2.5.3 Construction of scFv-FM3 
Mouse antibody heavy and light chain variable regions were amplified by PCR using a new 
set of primers specific to mouse IgG1, heavy chain λ and κ light chain (Table 3 and 4). 
Primers were used as forward and backward primers in mixes for mouse IgG1 single chain 
propagation. PCR reactions were carried out in a total volume of 50 l by adding 10 pmol of 
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each primer(s) and 1/10 to 
1/16 of the first strand cDNA reaction under the following 
conditions: intial denaturation at 95°C for 5 minutes followed by 35 cycles at 94°C for 1 min, 
55°C for 1 min, 72°C for 1 min and a final elongation for 10 min at 72°C. Antibodies heavy 
(VH) and light (VL) chain fragments were gel purified using “QIAquick gel extraction kit” 
(Qiagen) (II.2.1.12) and digested with different restriction enzymes from NEB: intermediate 
vector for VL HindIII and KpnI, intermediate Vector for VH PstI and BamHI, final vector: 
SfiI and NotI. After sequencing the new constructs were renamed to: pKF-VL, pKF-VH and 
pKF-SC. Digestion of intermediate vectors with KaspAI (Fermentas, Burlington, Canada) and 
dephosphorylation with Antartic Phosphatase (NEB) were done as described in the 
manufacturer‟s instructions. Digested DNA was purified from 0.7% UltraPure Agarose 
(Invitrogen) (II.2.1.11). Ligation was performed with T4 DNA Ligase (NEB) for 15 minutes 
at RT and 60 minutes at 37°C. Ligation products were electroporated into electrocompetent E. 
coli XL1 blue cells (II.1.4). 
 
II.2.6 Production of recombinant protein in N. tabacum 
II.2.6.1 Transient assay in tobacco leaves by vacuum infiltration 
Growth of recombinant Agrobacterium (II.2.1.9) and vacuum infiltration of tobacco leaves 
was performed as described by Kapila et al [173]. 
II.2.6.2   Preparation of recombinant Agrobacteria 
One hundred ml of YEB-Km-Rif-Carb medium was inoculated with 100 l of the glycerol 
stock of the selected recombinant agrobacteria carrying the plant expression vector. The 
culture was grown at 28°C o/n with shaking at 250 rpm. Next day the cells were pelleted by 
centrifugation at 5000 g for 10 min at 15°C and transferred into 250 ml of induction medium 
and cultivated at 28°C o/n with shaking at 250 rpm. Agrobacteria cells were centrifuged 
(4000 g/15-25°C/15 min) and resuspended in 50 ml of MMA solution and kept at RT for 2 h. 
The OD600 nm was measured after 1:10 dilution and the cell suspension was adjusted to an 
OD600 nm of 1. One hundred ml of the diluted cell suspension was used for vacuum 
infiltration of plant leaves (II.2.6.3). 
Induction medium: 
 YEB medium pH 5.6 
 MES 10 mM 
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2 mM MgSO4, 25 g/ml kanamycin, 100 g/ml rifampicin, 100 g/ml carbenicillin, 20 M 
acetosyringone were added after autoclaving and cooling. 
MMA buffer: 
 MS-salts (Murashige & Skoog, basic salt mixture) 0.43% (w/v) 
 MES; pH 5.6 10 mM 
 Sucrose 2% (w/v) 
 Acetosyringone was added directly before use 200 M 
II.2.6.3 Vacuum infiltration and syringe infiltration of intact leaves 
Young N. tabacum cv. Petite Havana SR1 leaves (4 leaves for each construct) were placed in 
100 ml of agrobacteria suspension in a “Weck” glass and a continuous vacuum (60-80 mbar) 
was applied for 15-20 min. The applied vacuum was released rapidly; the leaves were briefly 
rinsed in tap water and kept on wet Whatman paper no. 1 with adaxial side upwards. The 
plastic tray was sealed with saran wrap or the bacterial suspension was injected into the leaves 
from the hurt spots at the bottom side and placed at 22°C with a 16 h photoperiod for 60 h. 
Leaves were weighed, frozen in liquid nitrogen and stored at -80°C until analysis. As control, 
leaves were infiltrated with agrobacteria suspension, which did not contain the pTRA 
plasmid. 
II.2.6.4 Preparation of total soluble proteins from plant leaves 
For the extraction of transiently expressed E1 and scFv-FM3 in vacuum infiltrated tobacco 
leaves (II.2.6.3) or by syringe method of tobacco plant (II.2.6.4), frozen leaves were ground in 
liquid nitrogen to a fine powder with a mortar and pestle. Total soluble proteins were 
extracted using 2 ml of extraction buffer per gram leaf material. Cell debris was removed by 
two rounds of centrifugation (16000 g/4°C/30 min) and the supernatant was used for 
expression analyses by immunoblot (II.2.3.3). 
 
Extraction buffer: 
 Tris-HCl, pH 7.5 200 mM 
 EDTA 5 mM 
 DTT 0.1 mM 
 Tween 20 0.1% (v/v) 
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II.2.6.5 Purification of plant-produced HCV-E1 protein  
HCV-E1 protein was extracted from the plant tissue at small scale, by using NHS activated 
sepharose slurry. First the activated NHS was washed three times with (ice cold) 1 mM HCL. 
The sepharose was prepared by coupling the monoclonal antibody FM3 to (NHS)-activated 
sepharose (Pharmacia Biotech) according to the manufacturer‟s protocol. Briefly, 5 mg 
antibody dissolved in 1 ml coupling buffer (0.2 M NaHCO3, pH 8.3, 0.5 M NaCl), was loaded 
on to a 5 ml column of NHS-activated sepharose and allowed to stand for 30 min at room 
temperature. Unbound antibody was washed out of the column and any excess of active 
groups were deactivated according to the supplier‟s protocol. The supernatant of plant extract 
(pH 6-8) after being loaded was shacked gently for one hour at room temperature. The matrix 
poured in small batch purification tube, and then the column was washed three times with 10 
ml equilibration buffer and eluted with 3 M ammonium thiocyanate or 10 mM glycine HCl, 
pH 2.2. 
II.2.6.6 Purification of plant-produced scFv-FM3  
Tobacco plants having not more than 4 to 5 leaves each were used for vacuum assisted 
infiltration of recombinant agrobacteria. The plant material used in the experiment was 300 
grams. The leaves were harvested and immersed in the Agrobacterium suspension culture. 
After sixty hours post incubation the leaves were weighed without excising the central vein 
and stored at -80°C in liquid nitrogen. For total soluble protein extraction, the infiltrated 
leaves were ground in 2 ml of cold extraction buffer per gram of leaf material. The extract 
was filtered through Mira cloth (Calbiotech). The flow through was collected and centrifuged 
(10.000 g/4°C/30 min). The supernatant obtained after centrifugation was sequentially passed 
through Mira cloth and Whatman 3M paper. The pH of the plant extract was increased to 8 
and the extract was placed on ice for 30 min. The extract was centrifuged (10.000 g/4°C/30 
min), and filtered through Whatman 3M paper and applied to the Ni-NTA column for His6 
antibody purification (II.2.2.1). The matrix was equilibrated with three column volumes of 
PBS, pH 8 before application of the plant extract. The plant extract was passed through the 
column at a flow rate of 5 ml/min. The column was washed with PBS containing 100 mM 
NaCl (pH 8) till the online UV detector showed zero absorbance at 280 nm. The antibody 
fragment was eluted from the column with 150 mM imidazol (pH 8) under gravity flow. The 
first elution was of 500 µl followed by 4 batches of 2 ml fractions. The presence of the 
purified protein was verified by SDS-PAGE (II.2.3.2) and Western blot analysis (II.2.3.3). 
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III Results 
III.1 Cloning of truncated E1 and its cDNA fragments 
E1 cDNA gene (499bp) as well as truncated fragments E1F1-E1E6 of the same cDNA was 
amplified by PCR technique (II.1.6) (Figure 1). The E1 sequence of HCV genotype 1b was 
used as a template (cDNA provided kindly by Dr. Zentgraf, DKFZ, Heidelberg). The viral E1 
glycoprotein cDNA was designed without the transmembrane domain (TMD) in the template 
sequence, and by using specific primers (II.1.6) the produced cDNA fragments were designed 
in an equal size with 10 amino acids overlapping between (Figure 5) (for further use later in 
epitope mapping). The restriction sites NcoI and NotI were introduced into the forward and 
reverse primers for sub-cloning into desired vectors (II.1.6). The PCR products were directly 
cloned into pCR2.1-TOPO vector for sequencing 
 
 
Figure 5: Schematic representation of HCV-E1 viral cDNA used for generate small fragments for cloning 
and expression. HCV E1 was divided to six fragments (E1F1-E1F6) with 32-42 aa in length and overlapping in 
range ten amino acids to cover the E1 ectodomain, the restriction sites NotI and NcoI were introduced into the 
forward and reverse primers. 
 
The products were analyzed on 1.2 g (w/v) agarose gel electrophoresis (II.2.1.11) and the 
DNA fragments were purified from the gel. The pET26b(+) vector and the PCR products 
were cleaved by NcoI and NotI (II.2.1.17), then ligated with the T4 ligase enzyme (II.2.1.18). 
E1 cDNAs were subcloned into the NcoI/NotI of pET26b(+) vector, Target genes are cloned 
in pET plasmids under control of strong bacteriophage T7 transcription and translation 
signals. The expression is induced by providing a source of T7 RNA polymerase in the host 
cell. This system is able to maintain target genes transcriptionally silent in the uninduced 
state. The sequence upstream of the target genes is encoding a his6 tag protein and the N-
terminal pelB-leader sequence Fig. 6, which mediates protein transport into the periplasmic 
E 1  cDNA  499 bp 
E 1 F 1 
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compartment. This leader peptide is followed by E1 proteins and a 6x polyhistidine tag 
(6xHis-Tag), which allows protein purification by affinity chromatography. E. coli XL-1 blue 
was transformed directly with the recombinant plasmid by heat shock transformation 
(II.2.1.2), and bacteria were cultivated on kanamycin containing LB-agar plates. The colonies 
were picked and subsequently grown overnight in 5mL LB medium. The plasmid DNA was 
isolated by mini preparation method (II.2.1.2). The recombinant plasmids were identified 
through enzyme digestion (II.2.1.10) using the restriction enzymes NotI and NcoI. The 
sequence analysis of six clones confirmed the E1 cDNA in the right open reading frame and 
in the correct sequence into the pET26b(+) plasmid.  
                     
                                                           E1F6pelB
T7 P 
His6  
 
Figure 6: Expression cassette of E1 and overlapping truncated E1 fragments. The E1 proteins include T7 P: 
T7 promoter, pelB: leader sequence in the N-terminal, which mediates protein transport into the periplasmic 
compartment, this leader peptide is followed by E1 sequences flanking with NcoI and NotI restriction enzymes, 
His6: 6x polyhistidine tags which allows protein purification by affinity chromatography. 
 
III.2 Bacterial expression and purification of full size E1 and the six E1 
truncated fragments 
The full size E1 and the six truncated fragments of the HCV E1 recombinant glycoprotein 
were cloned to pET26b(+) vector and expressed in E. coli BL21 (DE3). In the pET26b(+) 
vector the synthesis of recombinant proteins is controlled by the T7 lac promoter. 
Additionally the vector contains a pelB sequence for the secretion of expressed proteins into 
the periplasm, also a C-terminal His6 tag for detection and purification. The results showed 
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the full size E1 and the truncated fragments E1F1-E1F5, which expressed in BL21 figure. 
Subsequently, C-terminal His-tagged proteins were purified using nickel-chelating resin by 
ion metal affinity chromatography IMAC on an ÄKTA-FPLC system following the 
manufacturers‟ instructions (II.2.3.5). The purified proteins were desalted overnight by 
dialysis (II.2.3.4) moreover, the proteins were sterile filtered and dissolved in PBS then stored 
at 4°C for subsequent use. The expressed proteins were analyzed with western blotting 
(Figure 7 and 8). Unfortunately, it was not possible to detect any significant expression for the 
expression of truncated fragments E1F6 protein.  
175
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Figure 7: SDS-PAGE and corresponding western blot recombinant E1 after IMAC purification. After 
separation of proteins by SDS-PAGE (II.2.3.2) the gel was stained with Coomassie Brilliant Blue (Serva, left). 
(Ft) flow throw, (W1) wash 1, (W2) wash 2 and (E1) elution protein, western blot (II.2.3.3) were detected using 
anti-his antibody (primary antibody) followed by a goat-anti-mouse-HRPO secondary antibody (Sigma) and 
Sigma Fast (Sigma) substrate. (M) Prestained protein marker, broad range (NEB). 
 
The integrity of E1 protein produced in bacteria was shown by SDS PAGE and western blot 
analysis. The detection was done by using anti-his antibody as a primary antibody (1:5000 
dilution) followed by a goat-anti-mouse horseradish peroxidase (HRPO) labeled as a 
secondary antibody (1:5000 dilution), then stained with sigma fast substrate (Figure 7), reveal 
the expression of E1 full size (26 kDa). E1 protein size was determined by comparison to 
prestained protein marker (NEB), AIDA software (Raytest, De). The IMAC elution fraction 
contains E1 protein was concentrated by the ultrafiltration process using membranes with a 30 
kDa cut-off. The protein reached the final concentration of 280 µg/l bacterial cultures. The 
analysis of E1 protein showed no contamination with bacterial produced proteins or 
degradation on SDS-PAGE or western blot analysis. The samples were stored at 4°C for 
further experiments. The E1F1-E1F6 truncated proteins were expressed and induced using 1 
mM IPTG for 8 hr at 37°C. Under these conditions E1 truncated fragments were produced as 
insoluble inclusion bodies. The following changes were made: induction time changed 
between 8 hr - 24 hr and temperature 18°C - 26°C were optimized to decrease the level of 
inclusion body formation and degradation of fusion proteins and the results revealed 24 hr and 
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18°C was the best conditions to produce the E1 truncated fragments. The recombinant 
proteins were extracted from 10 liters of bacterial culture and were purified under the 
denaturation condition with 8M urea (II.2.2.1). The fragments contain a 6His tag in the C-
terminal for Ni-NTA affinity purification; the proteins were purified subsequently by ion 
metal affinity chromatography IMAC on an ÄKTA-HPLC system, following manufacturers‟ 
instructions (II.2.3.5). After IMAC purification and dialysis the purity was verified on SDS-
PAGE (II.2.3.4). The E1 truncated proteins were separated and successfully detected in 
western blot (II.2.3.2 using anti His antibody (Figure 8). The recombinant E1 fragments 
proteins showed the expected size in range 7.0 kDa (Figure 4) and no contamination with the 
bacterial protein. The samples were sterilized by filtration and stored at 4°C for further 
experiments. The fragment E1F6 is the nucleotide sequences before the TMD region directly 
of the E1 glycoprotein. This sequence is rich in the Lysine base amino acid which has a 
positive charge, since the total charges play an important role in the ER retention of E1-
glycoprotein [112]. The pGEX-5x-3 plasmid was used instead of pET26b(+) to produce the 
truncated fragment E1F6, whereby the E1F6 was fused to the C- terminus of GST. The 
cloning was performed by NotI/NotI digestion and subsequent to pGEX-5x-3. The E. coli 
BL21-DE3 was used for expression of recombinant E1F6 fusion proteins (II.2.2.3). The GST-
fusion partner can stabilize short protein fragments and is also known to aid the proteins 
expression of difficult or toxic proteins in E.coli. The GST fusion protein encodes as well a 
Factor Xa cleavage site for later removal of the GST fusion part. E1F6 was expressed using 1 
mM IPTG concentration as inducer. The incubation temperature was varied between 30°C 
and 18°C and induction time was extended up to 8 hrs (Figure 9). Under all conditions E1F6 
did not give any significant expression and could not be detect by western blot analysis. The 
expected molecular weight of E1-F6 fused to the GST tag is estimated to be around 33.0 kDa. 
The result revealed one band in range 30 kDa and was also detected in the GST control. 
Table 9: Quantitative evaluation of the purified full size E1 and E1 truncated fragments produced from 
bacteria by Bradford assay. The final amount of purified proteins extracted from ten liters of bacterial culture. 
ELISA assay (II.2.3.5) was used to determine the total yield of the purified E1 and E1 truncated protein 
fragments produced in bacteria and purified via IMAC (II.2.2.3). 
 Total Yield (mg) Purified Protein (mg) 
HCV- E1 2.8 2.3 
E1F1 7.5 4.91 
E1F2 7.7 3.72 
E1F3 7.0 4.83 
E1F4 7.6 4.71 
E1F5 7.6 3.89 
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Figure 8: SDS-PAGE and immunoblot analysis of recombinant E1 truncated fragments after purification. 
SDS-PAGE (II.2.3.2) and corresponding Western blot (II.2.3.3) of recombinant E1 fragments after IMAC 
purification (II.2.2.3). F1-F5: The E1 truncated protein fragments.  (A) After separation of proteins by 12% (w/v) 
SDS-PAGE (II.2.3.2) the gel was stained with Coomassie Brilliant blue. (B) Proteins in western blot were 
detected using anti His antibody (primary antibody) followed by a goat anti- mouse-HRPO secondary antibody 
(Sigma) and Sigma Fast (Sigma) substrate. M: Prestained protein marker, broad range (NEB). 
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Figure 9: SDS-PAGE analysis of affinity purified GST fusion protein. E1F6 GST fusion protein was affinity 
purified using glutathione sepharose matrix (II.2.3.1). Purified proteins were separated on 12% (w/v) SDS-
PAGE gel then blotted onto a nitrocellulose membrane (II.2.3.3). Lane 1: Bacterial supernatant, lane 2: Flow 
throw, lane 3: wash 1, lane 4: elution protein. Immunodetection was carried out with anti-GST antibody 
(1:5000), followed by goat anti-mouse antibody (1:5000) conjugated to alkaline phosphatase and NBT/BCIP 
detection for 1 min at RT. 
 
III.3 Generation of E1-specific antibodies by hybridoma technology  
Immunization of four mice was carried out according to the immunization scheme shown in 
Figure 10. Mice were immunized in total seven times with 50 µg bacterial produced and 
affinity purified recombinant E1 protein at the given intervals (II.2.4.1). After the second 
boost polyclonal antibodies were obtained from mouse blood serum and the titer was 
determined by ELISA (Figure 11). 
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Figure 10: Immunization scheme. Three female mice (Balb/c) each were immunized with 50 g of 
recombinant HCV E1-His6 full size protein and 40µl GEBRU‟s adjuvant. Two further injections into the tail 
vein were given at biweekly intervals with the same amount of antigen and 20 µl GEBRU‟s adjuvant per mouse. 
The final boost was performed 1 day prior to sacrifice. 
 
ELISA was performed using recombinant E1 protein and BSA as a control (II.2.3.5). The 
defined antibody titer refers to the highest dilution of E1 antigen resulting in a twofold higher 
OD405 nm reading after 30 min of substrate incubation compared to the negative control. 
Titers of polyclonal mouse sera ranged between 1:120,000-150,000. No cross reactivity of 
polyclonal antibodies with BSA was detected for mice immunized with recombinant E1. 
100 ng E1 recombinant protein was coated per well and the serum of each mouse was applied 
in serial dilutions. Immunization triggered a relatively strong immune response with a titer of 
1: 64,000 (Figure 11) after one week of injection. Final titers of polyclonal mouse antibodies 
reached more than 1:250.000 indicating the high immunogenicity of the E1 protein. 
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Figure 11: Determination of polyclonal antibody titers from mouse antiserum by direct ELISA. 100 ng 
purified E1 full size protein was coated to ELISA plates (II.2.5.1). Serial dilutions of serum (after 1+4 weeks) 
minimum dilution were added to the coated plates and incubated for 2 hours at room temperature. Bound 
antibodies were detected by addition of goat anti-mouse polyclonal antibody (1:5000). ELISA reading was 
performed at OD405 nm after 1 h incubation with substrate at 37°C. 
 
 
III.3.1  Selection of E1 specific monoclonal hybridomas and isotyping of 
antibodies F39, FM1, FM3 and FM4 
After completion of immunization, three mice were sacrificed and the spleens were dissected 
for hybridoma generation. 1x108 spleen cells were successfully fused with 1x 107 Sp2/mIL-14 
myeloma cells (II.2.4.3). Additionally an equal amount of spleen cells was frozen and fused at 
a later time point. Hybridoma clones were cultivated at least 10 days to obtain at least 500-
1000 cells/clone before testing. Good fusion efficiency resulted in 500-1000 different growing 
hybridomas. After fusion the cells were cultivated for 7 days under HAT selection pressure. 
Until this time point single clones had expanded to 10-20 cells. In total 32 monoclonal 
hybridoma clones were obtained. The supernatants of these clones were tested in ELISA 
(II.2.3.5) for the production of E1 specific antibodies. To verify the binding of E1 an 
immunoprecipitation with subsequent ELISA analysis was also performed. ELISA was 
carried out as described (II.2.3.5). The supernatants of 32 hybridoma clones were tested 
(II.2.4.2). Figure 12 shows the results of 4 clones which showed binding to E1 antigen.  
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Figure 12: Specificity of E1 antigen specific monoclonal hybridoma clones. E1 specific monoclonal 
antibodies were characterized by ELISA (II.2.5.1). 100 ng of purified E1 was coated per well and subsequently 
incubated with 100 µl of hybridoma supernatant. Bound mouse antibody was detected with goat anti mouse-
HRPO. For detection, the ABTS substrate (Roche) was used and OD405 nm was measured after 30 min 
substrate incubation. 100 ng of BSA and HCV core protein were used as negative control. 
 
To determine the isotype of the obtained F39, FM1, FM3 and FM4 mAbs, an ELISA assay 
(II.2.5.1) was performed (BD Mouse Immunoglobulin Isotyping ELISA Kit). Indicating that 
all tested antibodies were of IgG1 type with kappa light chain except for the F39 which 
revealed no light chain (Fig. 13), therefore this antibody was excluded from further use. Each 
antibody was tested in a dilution of 1:100 from the hybridoma supernatant.  
 
Figure 13: Isotyping of F39, FM1, FM3 and FM4 mAbs by ELISA assay. The isotyping determined the types 
of the monoclonal antibodies by BD Mouse immunoglobulin isotyping ELISA kit (II.2.4.4). The antibodies were 
IgG1 with kappa light chain except the F39 that have no light chain therefore was no longer used in the next 
experiments. 
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III.3.2 Production and purification of FM1, FM3 and FM4 monoclonal 
antibodies 
After limited dilution the final clones FM1, FM2 and FM4 were expanded into tissue culture 
flask to enable mass production of monoclonal antibodies (500 ml). After growth the 
hybridoma culture supernatant was centrifuged to remove the cells and cell debris before 
applying it to the equilibrated protein G matrix for monoclonal antibodies isolation (II.2.2.2). 
The amount of purified antibody obtained was determined by ELISA (II.2.3.3) which was 7.0 
mg per liter of hybridoma culture supernatant (Figure 14). After purification the proteins were 
desalted overnight by dialysis (II.2.2.10). The affinity purified analyses of the mAbs FM1, 
FM3 and FM4by SDS-PAGE showed two distinct bands running at approximately 53 and 26 
kDa corresponding to the murine antibody heavy and light chains, respectively. The protein 
showed high purity on the SDS-PAGE (Fig. 14/A). The yields of purified monoclonal 
antibodies were estimated by ELISA assay (II.2.3.3); 10, 10 and 11 mg of FM1, FM3 and FM4 
from 200 ml culture volume. The measurements were made using high binding micro titer 
plates. The protein was immobilized by standard assay procedure as described in section 
(II.2.6.1). Serial dilutions were prepared from mAb 25 (kindly provided by Stefan Rasche) 
starting from 10 µg/ml, in order to generate standard curve reference. And labeled goat-anti 
mouse antibody was used for detection. According to the following formula, the mAbs were 
calculated. 
 
        mAb concentration =  average of absorption for 3 values X  dilution factor 
                                               Y for standand curve               1000 
 
The absorption is listed on the y-axis and the protein amount (µg) is shown on the x-axis. The 
corresponding standard curve exhibited a high linearity (10-40 µg/ml), with absorbance 
values ranging from 0.8 to 3.5 (n_6 at each concentration). 
 
  
III.3.3    Determination the functionality binding of mAbs FM1, FM3 and FM4 
against bacterial E1 protein 
FM1, FM3 and FM4 monoclonal antibodies were obtained as previously described from three 
different hybridoma clones selected against E1 antigen, and the binding activity of the 
purified monoclonal antibodies were tested by ELISA (II.2.3.5). As shown in (Figure 15) the 
purified antibodies were applied to E1-protein coated ELISA plates (serial dilution starting 
from 1000 ng down to 620 pg), the detected mAbs were up to 50 ng of protein/ml. 
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Figure 14: SDS-PAGE of the affinity purified mouse mAb FM1, FM3 and FM4. (A) The purified mAbs 
were separated on a 12% (w/v) SDS-PAGE gel and stained with Coomassie brilliant blue (II.2.3.2). FM1, FM3 
and FM4: 3 µg of the monoclonal antibodies after purification M: Molecular weight standard. (B) The purified 
mouse mAb amount was determined by ELISA assay (II.2.5.1). 
 
The detection was linear between 500ng and 50ng protein/ml. The purified monoclonal 
antibodies showed specific and high binding activity to E1 protein from which FM1 and FM4 
showed stronger reactivity compared to FM3 (Figure 15). In each case there was no binding 
observed to the control protein HCV core protein. 
 
Figure 15: ELISA for testing the binding activity of the FM1, FM3 and FM4 to E1 protein. The purified 
recombinant E1 protein dilutions were started from 50 ng/ml to 620 pg. bound mouse antibodies were detected 
with AP labeled GAM-Fc antibody. ABTS substrate (Roche) was used for detection and OD405 nm was 
measured after 30 min substrate incubation (II.2.5.1). The experiments were repeated at least three times. 
 
III.3.4 Epitope mapping of mAb FM1, FM3 and FM4 
In order to characterize the epitopes of mAb FM1, FM3 and FM4 linear, overlapping peptides 
of E1 were tested in ELISA for binding activity. The used peptides (E1F1 to E1F5) were 
equal in size and overlapping by 10 amino acid fragments have derived from E1-HCV virus 
 
Concentration 
of purified 
mAbs (mg/ml) 
Total 
amount of 
purified 
mAbs (mg) 
FM1 2 10 
FM3 2 10 
FM4 2.2 11 
E1 Concentration 
Control 
FM1 
FM3  
FM4 
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genotype 1b for epitope mapping. The monoclonal antibody FM3 bond to fragment E1F1 a 
peptide covering the amino acids derived from the region 191 to 252 aa 
(AMAYQVRNASGVYHVTNDCSNS), as well to E1 full size protein. No binding observed 
against the E1F2 fragment, which expected binding to the ten amino acid overlapping region. 
MAbs FM1 and FM4 bond to the E1F5 fragment (Fig. 16). This peptide covered the region 
containing the amino acids 322 to 353 aa (RMA WDM IMN WSP TTA LVV SQL LRI 
PQA VVD MV) of the E1 protein. Both antibodies did not detect any other peptide, so that 
the epitope could be also located in the overlapping ten amino acids which were also present 
in fragment 4. The epitope was detected by these mAbs, FM1 and FM4 presented in (Table 
10), fragment E1F5 located between the amino acids 313 to 327 near the C terminus of E1. 
The region was identified as a conserved sequence in E1-HCV genotype 1b in 1993. The 
antibodies were unable to react with peptides lacking any of other amino acids on other 
locations, suggesting that the three monoclonal antibodies recognized discontinuous epitopes 
requiring from which the entire sequence is needed for their formation (Table 10).  
 
Table 10: The amino acid sequence for E1 fragments E1-F1 to E1-F5 covered E1 full size. The bold 
sequences amino acids are the overlapping regions between fragments. 
 
E1F1 AMAYQVRNASGVYHVTNDCSNSSIVYEAADVI 191-225aa 
E1F2 SIVYEAADVIMHTPGCVPCVRENNSSRCWVALTPTLAARNSS 215-259aa 
E1F3 TPTLAARNSSIPTTTIRRHVDLLVGAAALCSAMYVGDFCGSV 249-292aa 
E1F4 MYVGDFCGSVFLVSQLFTFSPRRYETVQDCNCSIYPGHVSGH 282-323aa 
E1F5 SIYPGHVSGHRMAWDMIMNWSPTTALVVSQLLRIPQAVVDMV 313-353aa 
 
FM1 Monoclonal antibody
HCV-E1 protein
HCV core protein
BSA 
E1F1     E1F2      E1F3    E1F4      E1F5       E1
O
.D
 4
05
 n
m
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FM3 Monoclonal antibody
HCV-E1 protein
HCV core protein
BSA 
E1F1     E1F2      E1F3      E1F4      E1F5        E1
O
.D
 4
05
 n
m
 
E1F1     E1F2    E1F3     E1F4   E1F5      E1
O
.D
 4
05
 n
m
HCV-E1 protein
HCV core protein
BSA 
FM4 Monoclonal antibody
 
Figure 16: Epitope mapping of mAb FM1, FM3 and FM4 by ELISA. Epitope mapping of mouse monoclonal 
antibodies FM1, FM3 and FM4 binding to HCV-E1 protein by direct ELISA (II.2.8.1). 100 ng/well of bacterial 
purified E1 protein and E1 (F1-F5) fragments (II.2.2.3) were coated on microtiter plates. 100ng/well mAb was 
added in PBS to a final volume of 100μl. Bound mAb was detected by addition of 1:5000 diluted goat-anti 
mouse polyclonal antibodies conjugated to alkaline phosphatase as secondary antibody (1:5000). ELISA 
readings (OD405 nm) were performed after 30 min incubation with NBT substrate at 37°C. The experiments 
were performed at least three times for each.  
 
III.4   Antibody single chain generation 
 
III.4.1    cDNA synthesis, PCR amplification of antibody variable heavy and light  
chain fragments and sequence analysis 
Total RNA was isolated from hybridoma cells producing the mAb‟s FM1, FM3 or FM4 in 
order to rescue the genetic information of the antibody. The RNA concentration and the purity 
of the isolated total RNA was determined by spectrophotometry. The yield of total RNA 
isolated from an individual mouse ranged between 1-1.5 mg. The integrity of the RNA was 
checked on a 1.2% (w/v) agarose gel (Figure 17). The 28S and 18S ribosomal RNA were 
visible as distinct bands whereas the mRNA was present as background smear indicating the 
good quality and integrity of the isolated total RNA. Total RNA was used for PCR 
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amplification of antibody variable heavy (VH) and light (VL) chain fragments. Five μg RNA 
was reverse transcribed for first strand cDNA-synthesis using primers (II.1.7) binding to the 
constant regions of mouse heavy and light chain gene. Mouse IgG1 heavy chain variable 
region and variable fragments from the λ and κ light chain were amplified with primer 
combinations listed in (II.1.7).   
 
 
 
 
 
 
 
 
 
Figure 17: Analysis of FM1, FM3 and FM4 total RNA isolated from mouse hybridoma cells. Total RNA 
was isolated from hybridoma cells (II.2.6.1) and separated on a 1.2% (w/v) agarose gel containing 2.4 M 
formaldehyde (II.2.1.11). The major ribosomal RNA species (28S and 16S rRNA) can be seen clearly. 
 
Forty seven individual PCR reactions were performed to amplify VH and VL fragments for 
each clone of FM1, FM3 and FM4 cDNA. The primer combinations were used to amplify the 
products of heavy chain subclass IgG1 and from the κ light chain Figure 21. The PCR 
products of the light chain were ~750 bps and the heavy chain products were ~ 1500 bps in 
size after amplification (Fig. 18). 
 
  FM1 FM3 FM4  C       M       C      FM1   FM3   FM4 
   
Figure 18: Agarose gel electrophoresis of the assembled antibody heavy and light chains. The variable 
region of the heavy chain of the mouse mAb´s FM1, FM3 and FM4 (~1500 bp) and the variable region of the 
light chain of the mouse mAb´s FM1, FM3 and FM4 (~750 bp) (II.2.5.2) were separated on a 1.2% (w/v) 
agarose gel (II.2.1.11). M=2 log kb DNA ladder. 
28S RNA 
16S RNA 
M FM1 FM3 FM4 
1000bp 
500bp 
100bp 
Light chain 
3000bp 
1000bp 
500bp 
Heavy chain 
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The generated heavy and light chain variable cDNA were amplified and sequenced. The 
results revealed three different monoclonal antibody sequences (Fig. 19 and 20). The ExPasy 
database was used to compare the three sequences of antibody variable heavy and light chain 
sequences, and revealed the variable heavy and light chain fragments belong to mouse IgG/K 
type. Alignment of the variable domains of the three monoclonal antibodies FM1, FM3, and 
FM4 showed differences in the CDR regions for the monoclonal antibody heavy and the light 
chains (Fig. 19 and 20) of the monoclonal antibodies. The CDR1 differenced completely 
except two amino acids were similar. CDR2 completely different but the mAbs FM3 and 
FM4 lacked one amino acid and the CDR3 lacked in two amino acids for the mAb FM1. For 
antibody light chain, the CDR1 and CDR2 of all mAbs were completely different and CDR3 
had one amino acid similar for the three mAbs. The change in the framework regions didn‟t 
affected in the binding activity of the antibodies to recombinant E1 protein as was confirmed 
by ELISA. 
 
VH domain 
 
CDRH1
FM1 E I Q L V Q S G P E L K K P G Q T V E I S C K A S G Y D F T N Y G S N W V R Q A P G    
FM3 * V * * Q * * * A * * V R S * * S * K L * * T * * * F N I Q D * Y I Q * * K * R * E
FM4 * I * * Q * * * A * * V R S * * S * I L * * K * * * S T V T S * W G H * * K * R * G 
CDRH2
FM1 K D L K W K W M D I N T W I G E P T Y A D D F K R R F A F S L L N D G A E Y V N Q T
FM3 Q * * * * I * * S D P E N G D T E - * * * K * Q G K * * * * * A * * S N * * * L * * 
FM4 Q * * * * I * * I H P G S S N S N - * * * R * K S K * * * * * A * * S S * * * M * * 
CDRH3            
FM1 I N G N P K N T S T Y Y C A R N T R T D A N D - - Y P A M E Y W G Q G T S V T V S S
FM3 S S * T * A G I * V * * * N A W E T V I T T V L D * * * * E Y * * * * * * * * * * *
FM4 S S * T * M S S * V * * * T R S A D Y F N R S Y N * * * * D F * * * * * * * * * * *
 
Figure 19: Alignment of variable domains heavy chain amino acid sequences of the FM1, FM3 and FM4 
monoclonal antibodies. Framework regions and complementary determining regions (CDRs). „*‟: the same 
amino acid as above; „-„: no amino acid at this position. The complementary determining regions are indicated. 
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VL domain 
V A 
A * * * L E S * I * A * * S * * * * G T 
L * * * L A S * V * A * * S * * * * G T 
D R * * * * * * * * * * * * 
CDRL1
FM1 D I V L T Q S P A K A M Q M P V T E M S T C K A S K L G N M L T Q V W Y Q Y A H 
FM3 * * * * G * * S * S L A V S L G Q R A T I * *   * *   Q S V D Y D G D S * Y * * * D 
FM4 * * * * M * * S * T * M S A * P * E * * V * * * * S P M S G M A A M * * * S - -
CDRL2        
FM1 V T A A F Y K K Q P S K Q L L I Y L E D G V P I R Y T Q V P D Y I T G A M G
FM3 Y D G * - * * * * * * G * * * * * A A S
FM4 - * * * * * * * * * * R * * * * * W G E
CDRL3    
FM1 T Y S L T I S Q D Q A T T Y Y C S G * N G T T Y S Y P Y T F G G G T K L E L K R
FM3 * * * * N * H * * E E * * * * * Q Q * E D * F G G G
FM4 * * * * T * S * * E A * * * * * K M * D A * T W S S P P * * * * * * * * * * * *  
 
Figure 20: Alignment of variable domains light chain amino acid sequences of the FM1, FM3 and FM4 
monoclonal antibodies. Framework regions and complementary determining regions (CDRs). „*‟: the same 
amino acid as above; „-„: no amino acid at this position. The complementary determining regions are indicated. 
 
III.4.2      Construction of scFv-FM3 and sequence analysis 
The strategy shown below was used to clone the VH and the VL fragment of antibody FM3 in 
the form of a single chain fragment to enable recombinant expression in E. coli (II.2.2.3). 
FM3 monoclonal antibody revealed high binding activity against the recombinant E1 protein 
more than the other two monoclonal antibodies (FM1 and FM49, so the scFv-FM3 cDNA was 
chosen to be generated. The method used here is based on a primer set which is capable of 
amplifying VH and VL after cDNA synthesis with gene specific primers (II.1.7) binding upon 
the constant region. The primers discussed in the front encode no restriction sites and are not 
degenerated. The amplified sequence is cloned blunt ended into an intermediate vector (pKF-
VL or VH) digested with KaspAI (Fermentas) which is an isoschizomer of HpaI (NEB). 
Different experiments showed the number of realigns after dephosphorylation and the number 
of transformed uncleaved vector was much lower for KaspAI in comparison to HpaI. For 
cloning and to improve ligation efficiency the VH or VL fragments were 5‟ phosphorylated 
prior cloning. The 5´-3´ orientation of the PCR product in the intermediate vectors was 
controlled by sequencing. In a second step VL and VH were cloned into the final vector 
(pKF-sc). The scFv-FM3 cDNA can be expressed in this vector by secretion into the 
periplasm of E. coli. For later purification the scFv-FM3 is then transcribed in frame with a c-
myc and his-tag.  
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Figure 21: Schematic presentation of cloning procedure followed for construction of mouse scFv 
fragments. pKF-VH and pKF-VL are intermediate vectors for heavy (VH) and light (VL) chain which are blunt 
ended via KaspAI before adding the blunt end PCR products. Inserts which are oriented against the ORF of lacZ 
have the correct orientation for further cloning. The light chain is cloned via AscI and NotI into pKF-sc (vector 
containing the corresponding VH fragment. pelB: pelB leader peptide; cmyc: and His epitope for the scFv 
detection; 218 linker) before the heavy chain is added via SfiI and PacI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Amplified VH and VL of FM3 monoclonal antibody. The gel (1.2% agarose, 35 minutes with 
110V) shows the amplified of V genes of the FM3 which is of the IgG1 isotype. Lane 1: FM3 light chain cDNA, 
lane 2: FM3 heavy chain cDNA. The heavy chain is encoded by more bases in comparison to the light chain 
which can be seen within this gel. M: DNA ladder 100 bp (NEB). 
 
scFv-FM3 constructed for further experiments like co-expression with E1 protein in plant. In 
a first step the positive cloned cDNA fragments were sequenced, aligned and the positive 
VH VL 
VH 
SfiI PacI AscI NotI
1 
      pKFsc vector library 
AscI/NotI digest 
SfiI/PacI digest 
Antibody Heavy chain cDNA pool  Antibody light chain cDNA pool  
PCR PCR 
PCR PCR 
VH VL Linker c-Myc His6     stop codon - AUG 
 
Leader 
SfiI NotI 
VL pKF-VL  
vector 
pKF-VH   
vector 
PacI AscI 
`5 -  
300bp 
FM3 light chain 
2 1 M 
FM3 heavy chain 
100bp 
500bp 
-3„  
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clones were selected. The scFv-FM3 clone had encoded for an open reading frame of 31 kDa. 
The sequence of scFv-FM3 was analyzed with numerous computational analysis tools 
available online through the World Wide Web for antibody sequences. The standard Kabat 
numbering for the scFv-FM3 sequence was assigned by submitting the sequence to 
http://www.bioinf.org.uk/abs/seqtest.html.This tool provides an automated alignment facility 
with the consensus sequence. Once the Kabat numbering was assigned to scFv-FM3sequence 
the complementary determining regions (CDRs) and the framework regions were easily 
identified by comparison with the Kabat protein database. The database is used to identify 
amino acid residues occurring in less than 1% of the data in the database. The scFv-FM3 
sequence was found to be devoid of any such unusual residues. The sequence alignment of the 
scFv-fragment with IMGT databases (http://imgt.cines.fr/IMGT_vquest/) indicated that the 
variable heavy and light chain fragments were members of different groups. Notably 
divergences could be observed from the closely related germline V-genes in the nucleotide 
and respectively on the amino acid level. (Table 11) summarizes the sequencing results of the 
scFv-FM3. The deduced amino acid of scFv is presented in (Figure 23).  
Table 11: Summary results of scFv-FM3 derived nucleotide length and deduced molecular weight of scFv 
specificity to E1 antigen.  
 
 
 
MAEVQLQQSGAELVRSGASVKLSCTAS GFNIQDYYIQWVKQRPE
QGLEWIGWMSDPENGDTE-YAPKFQGKATMTADTSSNTAYLQLSSL
TSEDIAVYYCNAWETVITTVLDYPMEYWGQGTSVTVSS NLIKGG
GSGGGSGGGSGAPVDIVLTQSPASAVSLGQRATISCKA SQSVDYD
GDSWYQYADYDGA-YKPGQPPKLLIYAASNLESGIPARFSGSGSGTD
FTLNIHPVEEEDAATYYCQQSEDTFGGGDRTFGGGTKLELKR
CDRH1
CDRH2
CDRH3
Linker CDRL1
CDRL2
CDRL3
 
 
Figure 23: Deduced amino acid sequences of selected mouse scFv-FM3 fragment. The amino acids sequence 
of scFv-FM3. The complementary determining regions (CDR 1, 2, and 3) are shown. The complementary 
determining regions and the 218 linker have been indicated. 
Designation of scFv Nucleotide length (bp) Deduced MW (kDa) 
scFv-FM3 768 31.0 kDa 
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Table 12: The V-gene family of scFv-FM3 specific to recombinant E1 protein. The alignment of the selected 
scFv-FM3 to the gremlin gene sequences most closely related to the IMGT database 
(http://imgt.cines.fr./imgt_vquest/). 
 
scFv 
Mouse/Human 
IgG Family 
Closest germline gene 
sequences 
Identity (Nucleotides) 
VH VL VH VL VH VL 
scFv-FM3 IGHV5 IGKV8 M98670 X69355 
94.44% 
(279/288 nt) 
95.77% 
(274/279 nt) 
 
II.5 Production of recombinant HCV-E1 and scFv-FM3 in tobacco plant 
The aim of this work was development of a technology for HCV vaccine production using the 
E1 ectodomain as a virus like protein target. Additionally, this project was aimed at the 
establishment of an antibody-based HCV diagnosis in the patient serum. The objective of this 
work was the production of recombinant E1 ectodomain in the plant production system as 
well as generation and characterization of E1-specific monoclonal antibodies and scFv 
fragment. In addition, the resulting scFv-FM3 fragment was characterized for the production 
level in tobacco plant.  
III.5.1 Cloning of E1 and scFv-FM3 into plant expression vector 
The E1 cDNA and scFv-FM3 cDNA was cloned into plant expression cassettes enabling 
secretion of the recombinant proteins to the plant apoplast, or retention in the ER where many 
recombinant proteins accumulate to higher levels. For secretion of the recombinant E1 to the 
apoplastic space, the E1 gene was amplified from pMSLGFP vector bearing the complete E1 
sequence of genotype 1b using primers based on the 5´ and 3´ sequence of the HCV 
ectodomain (II.1.6). Both restriction sites, NcoI and NotI were introduced in the forward and 
reverse primer, respectively. The 499 bp amplified PCR product was subcloned into the pCR-
4-TOPO vector. The correct E1 sequence was confirmed by sequencing. Subsequently, the 
NcoI/NotI digested E1 cDNA fragment was inserted downstream of the double enhanced 
CaMV 35S promoter, 5´ untranslated region of the chalcone syntheses. The plant codon-
optimized signal peptide sequence derived from the light chain of the TMV-specific murine 
antibody 24 and upstream of the c-myc and his6 tag sequences and the 3´ untranslated region 
of the CaMV 35S gene, into the plant expression vector pTRAkc-AH, resulting in the final 
construct pTRAkc-E1-AH (Figure 24/A). Targeting of the E1 recombinant protein to the 
lumen of ER was achieved by using a carboxyl-terminal Lys-Asp-Glu-Leu (KDEL) retrieval 
signal (Figure 24/B). Therefore, the E1 cDNA was cloned as described above, into the 
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-3„   
-3„   
-3„   
-3„   
`5 -  
`5 -  
`5 -  
`5 -  
pTRAkc-rfp-ER, upstream of the His6 and KDEL tag and the 3´ untranslated region of the 
CaMV 35S gene resulting in the final construct. 
A 
P35S CHS LPL E1 His6 Pw  
EcoR I
Nde I
Nco I
Sal I
Xba I
pTRAkc-E1-AH 
 
B 
P35S CHS LPL E1 His6 KDEL Pw
EcoR I
Nde I
Nco I
Sal I
Xba I Hind III
pTRAkc-E1-ER 
 
Figure 24: Schematic presentation of the final plant expression cassettes for retaining of E1 and secreting 
to apoplast (A), E1 to the plant cell ER (B). P35S: 35S promoter with doubled enhancer from Cauliflower 
Mosaic Virus (CaMV). CHS: 5' untranslated region of chalcone syntheses. LPH: plant codon optimized leader 
peptide derived from murine light chain of TMV-specific mAb24. E1: HCV-E1 glycoprotein cDNA. His6: his-6 
tag. KDEL: KDEL tag, Pw: 3' UTR of TMV RNA. 
 
To study the stability and functionality of scFv-FM3 in the plant cell apoplast and ER, the 
scFv-FM3 cDNA was amplified from pKFsc vector using specific primers introducing the 
NcoI and SalI restriction sites at the 5´ and 3´ sequence of the scFv-FM3, respectively. The 
800 bp amplified PCR product was subcloned into the PCR 2.1TOPO vector. The correct 
scFv-FM3 sequence was confirmed by sequencing. Then, the NcoI/SalI digested scFv-FM3 
fragment was cloned into the pTRAkc-rfp-AH or pTRAkc-rfp-ER plant expression vectors 
resulting in the final constructs pTRAkc-scFv-FM3-AH or pTRAkc-scFv-FM3-ER, 
respectively (Figure 25). 
            A 
P35S CHS LPL scFvFM3 His6 Pw  
EcoR I
Nde I
Nco I
Sal I
Xba I
pTRAkc-scFvFM3-AH 
 
B 
P35S CHS LPL scFvFM3 His6 KDEL Pw
EcoR I
Nde I
Nco I
Sal I
Xba I Hind III
pTRAkc-scFvFM3-ER 
 
Figure 25: Schematic presentation of the final plant expression cassettes for retaining of scFv-FM3 and 
secreting to apoplast (A), scFv-FM3 to the plant cell ER (B). P35S: 35S promoter with doubled enhancer 
from Cauliflower Mosaic Virus (CaMV). CHS: 5' untranslated region of chalcone syntheses. LPH: plant codon 
optimized leader peptide derived from murine light chain of TMV-specific mAb24. scFv-FM3: scFv of the 
monoclonal antibody FM3 cDNA. His6: his-6 tag. KDEL: KDEL tag, Pw: 3' UTR of TMV RNA. 
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The constructs pTRAkc-E1-AH, pTRAkc-E1-ER, pTRAkc-scFv-FM3-AH and pTRAkc-
scFv-FM3-ER were transformed into Agrobacterium tumefacience by electroporation. Ten 
randomly selected recombinant colonies from each transformation were screened for the 
presence of expression cassettes by colony PCR using the pSSH1 (II.2.2.8.2) specific primers 
(II.1.8.9). Recombinant Agrobacterium cultures were prepared from one PCR positive single 
colony of each construct and used for transient expression.  
III.1.2      Transient expression of E1 and scFv-FM3 in tobacco 
Transient expression experiments were performed for analysis of accumulation and stability 
of recombinant E1 and scFv-FM3 because the procedure is fast and not affected by e.g. 
position effects [113]. Five N. tabacum cv. Petite Havana SR1 plants were infiltrated using 
the syringe method with recombinant agrobacteria containing either pTRA-apo-E1, pTRA-
ER-E1, pTRA-apo-scFv-FM3 or pTRA-ER-scFv-FM3 constructs (II.2.2.1). Wild type N. 
tabacum plants were used as negative control. After three days of incubation, total soluble 
proteins were extracted (II.2.2.1) and 10μl were analyzed by immunoblot (II.2.4.4), to verify 
accumulation and integrity of the recombinant proteins. The immunoblot analyses showed a 
band of approximately 30 kDa corresponding to the molecular weight of scFv-FM3 for the 
ER retained protein (Figure 26, Line 2). The accumulation of the scFv-FM3 in the apoplast 
was below the detection level of the immunoblot (Figure 26/A, Line 4). These results 
indicated that the ER is the most suitable compartment for the scFv-FM3 production. No 
distinct bands were observed for the ER retained or secreted E1 recombinant protein when 
immunoblot detection was performed with the anti-his6 antibody (Figure 26/A, Line 3 and 5). 
To investigate if the low sensitivity of the anti-His6 antibody could lead to undetectable levels 
of E1 protein in immunoblot the E1-specific monoclonal antibody FM1 was used as a primary 
antibody for detection. Indeed, a distinct band of approximately 25 kDa was shown for the ER 
targeted E1 (Figure 26/B, Line 3), indicating that the mAbFM1 has a higher sensitivity 
compared to anti his6 antibody. Taken together these results indicate that the endoplasmatic 
space is the most suitable compartment for the production of scFv-FM3 and E1 recombinant 
proteins. 
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Figure 26: Transient expression of apoplastic and ER-targeted E1 and scFv-FM3. Total soluble leaf 
proteins were extracted by grinding tobacco leaf tissue in one volume extraction buffer (II.2.2.1) separated by 
SDS-PAGE (II.2.4.3) and blotted onto a nitrocellulose membrane (II.2.4.3).Immunological detection was carried 
out using anti-his6 as primary antibody (A) and mAb FM1 (B) in dilution 1:5,000, followed by alkaline 
phosphatase-conjugated goat anti-mouse as secondary antibody in dilution 1:5,000. Detection was performed 
with NBT/BCIP at RT in the dark. 1: 10μl total soluble proteins extracted from wild type tobacco leaves, 2: 10μl 
of total soluble protein extracted from tobacco leaves accumulating the scFv-FM3 in the ER. 3: 10 μl of total 
soluble protein extracted from tobacco leaves accumulating E1 in the ER. 4: 10 μl of total soluble protein 
extracted from tobacco leaves accumulating scFv-FM3 in the apoplastic space. 5: 10 μl of total soluble protein 
extracted from tobacco leaves accumulating E1 in the apoplastic space. M: prestained protein marker. 
 
III.5.3    Coexpression of E1 protein and scFv-FM3 in plants 
Previous studies performed in our laboratory have demonstrated an increase of the 
recombinant protein stability, integrity and/or accumulation levels by co-expressing a specific 
binding partner leading to the formation of a complex between the target protein and its 
binding site. In order to improve the accumulation of the E1 in tobacco plants, the 
recombinant E1 protein was transiently co-expressed with the scFv-FM3 targeted into the 
same (E1-apo/scFv-FM3-apo, E1-ER/scFv-ER) or different plant cell compartments (E1-
apo/scFv-FM3-ER, E1-ER/scFv-FM3-apo) (Table 13). After three days of incubation, 
accumulation of the E1 was verified by immunoblot analysis (II.2.3.2) using the same amount 
of the total soluble proteins extracted from infiltrated tobacco leaves. The E1 protein was not 
detectable by immunoblot analysis neither in the ER nor in the apoplast, when detection was 
performed with the anti-his6 antibody. In contrast, when the E1-specific monoclonal 
antibodies were used for the immunoblot detection (FM1, FM3 or FM4), bands of similar 
intensities corresponding to the molecular weight of the E1 (25 kDa) were detected in the ER 
when the E1 was expressed alone (Figure 27/B or C, or D line 3) or co-expressed with the 
scFv-FM3 in the ER (Figure 27/B or C, or D line 6) or apoplast (Figure 27/B or C, or D line 
9), respectively. Moreover, the immunoblot analysis revealed that the mAb FM3 showed the 
highest sensitivity to the plant produced E1; therefore this antibody was selected for further 
analysis. The same amount of the scFv-FM3 was retained in the ER when the scFv was 
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targeted alone (Figure 27/A, line 2) or in combination with the apoplastic (Figure 27/A, line 
6) or ER retained E1 (Figure 27/A, line 7), respectively. Taken together these data confirmed 
that the ER is the most suitable compartment for the E1 production in plants and coexpression 
of the E1-specific recombinant antibody (scFv-FM3) could not improve the E1 accumulation 
levels.  
III.5.4    Time course analysis of recombinant E1 and scFv-FM3 protein 
accumulation in tobacco plants 
In order to optimize the yield of E1 and scFv-FM3 production the time course technique was 
used. During incubation time at maximum six days, plant samples were obtained at defined 
time points and recombinant protein production was analyzed. The relative amounts of 
recombinant protein were compared using SDS PAGE and immunoblot analysis. Visual 
examination of the gel reveals that over a period of six days, the amount of the protein 
increased to an apparent maximum. Time-course analysis showed that the recombinant E1 
protein started to accumulate in the ER at the 2 days post infiltration reaching its maximum at 
the 4th day post infiltration (Figure 28/B). As previously indicated, co-expression of the scFv-
FM3 had no effect on the E1 accumulation levels as showed from the western blot. A 
production level of the E1 in the apoplastic space was under immunoblot detection levels 
during the time-course analysis. Time-course analysis showed maximum accumulation of the 
scFv-FM3 protein reached at day 6 post infiltration. E1 accumulation cannot be detected by 
immunoblot analysis since the scFv-FM3 can be detected by anti his antibody.  
Table 13: Shows the different individual plasmid constructs and the mixes thereof for coexpression of E1 
protein and scFv-FM3, the number indicates to plasmids in next experiments. 
 
Overview of coexpression set-up No. 
pTRA-ER-scFv-FM3 2 
pTRA-ER-E1 3 
pTRA-apo-scFv-FM3 4 
pTRA-apo-E1 5 
pTRA-ER-scFv-FM3 + pTRA-ER-E1 6 
pTRA-ER-scFv-FM3 + pTRA-apo-E1 7 
pTRA-apo-scFv-FM3 + pTRA-apo-E1 8 
pTRA-apo-scFv-FM3 + pTRA-ER-E1 9 
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Figure 27: Transient co-expression of the E1 and scFv-FM3 in tobacco leaves. Total soluble protein was 
extracted from the leaf by grinding tissue in one volume extraction buffer (II.2.2.1) separated by SDS-PAA 
(II.2.4.3) and blotted onto a nitrocellulose membrane (II.2.4.3). Immunodetection was carried out with anti-his6 
as primary antibody (A), mAbFM1 (B), mAbFM3 (C) and mAbFM4 (D) respectively (1:5000 dilution), 
followed by alkaline phosphatase-conjugated goat anti-mouse as secondary antibody. Detection was performed 
with NBT/BCIP at RT in the dark. 10 μl total soluble protein extracted from tobacco leaves was loaded. 1) Wild 
type control, 2) pTRAkc-ER-scFv-FM3, 3) pTRAkc-ER-E1, 4) pTRAkc-AP-scFv-FM3, 5) pTRAkc-AP-E1, 6) 
pTRAkc-ER-scFv-FM3 & pTRAkc-ER-E1, 7) pTRAkc-ER-scFv-FM3 & pTRAkc-AP-E1, 8) pTRAkc-Ap-
scFv-FM3 & pTRAkc-AP-E1 and 9) pTRAkc-AP-scFv-FM3 & pTRAkc-ER-E1 respectively. M) prestained 
protein marker. 
 
The E1 protein was detected using the three monoclonal antibodies but the immunoblot 
analysis showed high sensitivity detection by using FM3> FM4 > FM1, respectively, that 
meant the accumulation yield of E1 is below the detection level by the immunoblot analysis 
and could be the post transcription process was hidden the His6 tag inside the recombinant E1 
produced protein that led to the difficulty in the detection.  
 
 
 
 
 
 
coexpression 
coexpression coexpression 
coexpression 
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Figure 28: Time course analysis of E1 and scFv-FM3 accumulation in ER and apoplast. Total soluble leaf 
protein was extracted by grinding tobacco leaf tissue in one volume extraction buffer (II.2.2.1) separated by 
SDS-PAA (II.2.4.3) and blotted onto a nitrocellulose membrane (II.2.4.3). Immunodetection was carried out 
using anti-his6 as primary antibody (A), FM3 mAb (B) respectively (1:5000), followed by alkaline phosphatase-
conjugated goat anti-mouse as secondary antibody (1:5000). Detection was performed with NBT/BCIP at RT in 
the dark. 10 μl of total soluble protein extracted from tobacco leaves was loaded. 1) Wild type control, 2) 
pTRAkc-ER-scFv-FM3, 3) pTRAkc-ER-E1, 4) pTRAkc-AP-scFv-FM3, 5) pTRAkc-AP-E1, 6) pTRAkc-ER-
scFv-FM3 & pTRAkc-ER-E1, 7) pTRAkc-ER-scFv-FM3 & pTRAkc-AP-E1, M: Prestained protein marker. 
 
III.6   Purification and quantification of plant produced E1 and scFv-FM3 
proteins 
Total soluble protein was extracted from tobacco leaves transiently infiltrated with 
Agrobacteria carrying the pTRA-ER-E1 plasmid (II.2.2.1). The obtained total soluble protein 
was subjected to immobilized metal affinity chromatography (IMAC) (II.2.3.5). 
Unfortunately, all efforts to purify plant produced E1 via IMAC failed therefore; affinity 
chromatography using the mAb FM3 bound to NHS activated sepharose matrix (II.2.3.6) was 
used as an alternative strategy. Samples from all purification steps were analysed by SDS-
PAGE and immunoblot analysis. Analyses of the affinity purified E1 showed one distinct 
band running at approximately 25 kDa (Figure 29/A, lane 5) corresponding to the expected 
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molecular weight of E1. The eluted protein showed high purity in SDS-PAGE and no 
degradation bands were revealed by immunoblot analysis. Furthermore no bands 
corresponding to the E1 protein were observed in the flow through and wash samples, 
indicating a high purification efficiency using the mAb FM3 enriched matrix. The average 
yield of E1 was estimated by ELISA assay (II.2.4.1) to be 8.4 mg per kg of fresh leaf weight 
(Table 14). Small scale infiltration of tobacco leaves (300 grams) was performed for 
purification of the scFv-FM3 for further characterization. The purification of the His6-tagged 
scFv-FM3 was performed by immobilized metal affinity chromatography (IMAC) using the 
Ni-NTA matrix (II.2.5.3). The immunoblot analysis of affinity purified scFv-FM3 revealed a 
distinct band at ~32 kDa corresponding to the expected size of correctly processed scFv-FM3 
fragment (Figure 30). 
               A                                                                                  B 
                           
 
Figure 29: SDS-PAGE and immunoblot analysis of affinity purified E1 by NHS activated sepharose 
matrix immunoaffinity chromatography. Affinity purification of recombinant E1 protein was expressed in the 
ER. Ten μl of total soluble protein was separated on a 12 % (w/v) SDS-PAA gel (II.2.4.3) and analysed by 
immunoblot (II.2.4.4). (A) SDS-PAGE of E1 obtained from the ER. 1) leave extract, 2) flow through, 3-4) wash, 
5-6) elution fractions; (B) immunoblot analysis of E1 obtained from the ER. 1) Leave extract, 2) flow through, 3-
4) wash, 5-6) elution fractions, M) pre-stained marker for immunoblot. Immunodetection was carried out with 
FM3 monoclonal antibody as primary antibody and goat anti-mouse polyclonal antibodies conjugated to alkaline 
phosphatase as secondary antibody (both diluted to 1:5000) followed by addition of the NBT/BCIP substrate. 
Another light band of ~28 kDa, probably scFv-FM3 degradation, was observed in all the 
analysed samples when detection was performed with anti-His6 antibody (Fig. 30). 
Furthermore, a faint band corresponding to the scFv-FM3 was obtained from the flow through 
and the wash samples, which indicates losing of the scFv-FM3 protein during IMAC 
purification. The yield of scFv-FM3 was estimated by ELISA assay, which was 125 mg per 
kg fresh leaf weight in the crude extract and 3.1 mg per kg of fresh leaf weight after 
purification. That reflects the efficiency of the purification assay. The immunoblot analysis of 
the plant purified scFv-FM3 was performed with antibodies specific to the tag present at the 
3´ terminal of the scFv-FM3 i.e. the His6 tag (Fig. 30).  
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Figure 30: Immunoblot analysis of Ni-NTA purified scFv-FM3from tobacco leaves. The purified scFv-FM3 
was analyzed on a 12% (w/v) SDS-PAGE gel and analyzed by immunoblot analysis. Lane 1: 10 µl of flow throw 
samples Lane 2: 10 µl of total soluble protein extracted from the infiltrated tobacco leaves of scFv-FM3 (II.5.3); 
Lane 3: 10 µl of column wash samples; Lane 4: 5 µl of the elution M: Molecular weight standard, scFv-FM3 was 
detected by mouse anti-His6 antibody. AP labeled GAM-Fc antibody was used as the secondary antibody. 
 
The amount of E1 produced in plants was 30-fold higher compared to the yields observed 
from E. coli, indicating that plants are more suitable for recombinant E1 production. The 
amount of scFv-FM3 protein produced in plants was 10-fold higher compared to bacteria 
produced scFv-FM3, indicating that plants are more suitable for recombinant scFv-FM3 
production. 
 
 
Table 14: Evaluation of the E1 and scFv-FM3 protein production in E.coli and tobacco. Listed is the 
average yield of the recombinant E1 and scFv-FM3 proteins as estimated by ELISA, n= number of the biological 
replicate 
 
Purified Protein Mean±SD (n=3) 
E1-Bacteria 280 ± 3.2 ug/L 
E1-Plant (tobacco) 8.4 ± 0.85 mg/kg 
scFv-FM3-Bacteria 300 ±3.4 ug/L 
scFv-FM3- Plant(tobacco) 3.1±0.73 mg/kg 
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III.7 Binding reactivity of plant extracted E1 against recombinant expressed 
scFv-FM3 
The binding of the affinity purified scFv-FM3 from bacteria and plant against purified 
bacteria or plant E1 recombinant protein was tested by direct ELISA (II.2.3.5). The HCV core 
protein was used as negative control. The same amount of the bacterial and plant purified 
single chain (100 ng/well) was applied to bacterial E1, plant E1 and HCV core protein coated 
ELISA plate starting from 100:20 ng/well dilution (Figure 31), showed the specific binding of 
the scFv-FM3 to bacterial and plant purified E1 in ELISA. The scFv-FM3 binding to the plant 
produced E1 is up to 2-fold higher than binding to bacterial produced E1, indicating a higher 
functionality of the plant produced scFv, which may be due to the glycosylation plays role in 
reaction enhancement the reactivity with the recombinant protein like HCV core protein. The 
differences that can see between scFv-FM3 binding to the bacteria and the plant produced E1 
might be related to the different sensitivities of the anti- His6 and anti-myc antibodies used for 
the detection. The reactivity binding of the scFv-FM3 against the E1 protein in ELISA assay 
showed the cross reactivity between the scFv-FM3 and the protein in control was very low. 
The signal to noise ratio indicated (Figure 31) there activity ratio which is more than 0.4 
between the scFv-FM3 (produced in bacteria) from the scFv-FM3 (produced in plant) of E1 
antigen produced in plant. Even though the E1 antigen produced in bacteria did not show a 
big different in the reactivity to the scFv-FM3, the signal noise ratio to HCV core protein was 
low indicated a high specificity to E1 produced in plant.  
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Figure 31: Characterization of scFv-FM3 protein against recombinant E1 bacterial and plant produced 
protein. Binding of scFv-FM3 to HCV-E1 protein (from bacteria and plant) after expression and purification 
was evaluated by direct ELISA (II.2.8.1). The same amount of the bacteria and plants purified scFv-FM3 (100 
ng/well) was applied to bacterial or plant produced and purified E1 protein coated into ELISA plate in 
concentrations of 100 ng/well. Bound scFv was detected by addition of 1:5000 diluted anti-myc monoclonal 
antibodies (for E1 bacteria), antiHis6 antibodies (for E1 plant) and goat-anti mouse polyclonal antibodies 
conjugated to alkaline phosphatase as secondary antibody (1:5000). ELISA readings (OD405 nm) were 
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performed after 30 min incubation with NBT substrate at 37°C. Shown are mean values from three independent 
experiments. Standard deviations are shown with error bars.  
 
III.8   Use of E1-specific mAbs in HCV diagnostic 
 
III.8.1 Detection of recombinant E1 in sandwich ELISA 
 
The monoclonal antibodies FM1, FM3, FM3 and the recombinant HCV-E1 protein were used 
to establish a double-antibody sandwich ELISA (s-ELISA) for detecting the viral HCV type 
1b. The mAbs were labeled with horseradish peroxidase (HRP-labeled) to provide us with the 
possibility to detect the antibodies in s-ELISA. The s-ELISA setup was required to establish 
and identify every step's requirement, before the manipulation of the infected sample with 
HCV. The setup of sandwich ELISA determined the protein concentration, the suitable 
different monoclonal antibodies' combination and the needed time for the reaction 
visualization of the experiment. The combination of labeled and unlabeled FM1, FM3 and 
FM4 mAbs concentration was used (highest concentration was 40μg/ml), depending the type 
of detection antibody. The ELISA plates were coated with unlabeled FM1, FM3 or FM4 as a 
primary antibody, then the recombinant E1 protein was applied and finally the FM1HPR, 
FM3HPR or FM4HPR was used as detection antibody. The optimum dilutions of capture and 
detection antibody were selected using a chequer board type titration against fixed 
dilution/concentration of E1 recombinant protein. The most satisfactory result was obtained at 
a dilution of 1:2 for the primary antibody and 1:8 for the detection antibody, while the 
dilution of the positive antigen and protein control were determined to be 1:5. The results 
revealed the best combinations to detect the recombinant HCV-E1 protein by s-ELISA 
confined in three different mixtures FM1/FM4HPR, FM4/FM1HPR and FM1/FM3HPR (Table 
15). The signal to noise ratio was estimated higher than < 6. The combination FM4/FM1HPR 
(Figure 32/A) showed the monoclonal antibody FM4, which gave a noise ratio of more than 
4, while, the noise ratio of FM1 was more than 1 and the results revealed high cross reactivity.  
The combination FM1/FM4HPR (Figure 32/B) showed the monoclonal antibody FM1 which 
gave a noise ratio greater than 3, while, the noise ratio of FM3 was more than 0.5. The results 
showed cross reactivity between some mAbs combination, so this combination with confusion 
was removed from the work. The combination FM1/FM3HPR (Figure 32/C) showed the 
monoclonal antibody FM3 gave a noise ratio more than 4.5, while the noise ratio of FM3 was 
larger than 3. The s-ELISA revealed no cross reactivity between E1 and the control. These 
dilutions and concentrations were maintained and followed throughout the study. 
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Table 15: The combination between the three monoclonal antibodies FM1, FM3 and FM4 for sandwich 
ELISA setup using recombinant E1 protein. The combination between the labeled and non-labeled 
monoclonal antibodies FM1, FM3 and FM4 showed four different types of the results, (*) no reaction against 
recombinant E1 protein, (#) confusing results, (++) accept all results with some cross reactivity against the 
control protein and (++++) good results against recombinant E1 protein. 
 
 
 FM1 FM3 FM4 
FM1
HRP
 # * ++ 
FM3
HRP
 ++++ # * 
FM4
HRP
 ++ * # 
 
The average/N (OD405) values for the positive and negative antigen controls generated in the 
s-ELISA was slightly lower than the other's samples. 
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Figure 32: The sandwich ELISA setup of FM1, FM3 and FM4 against recombinant HCV-E1 protein. The 
sandwich ELISA (II.2.3.5) of FM1, FM3 and FM4 mouse monoclonal antibodies binding to HCV-E1 protein 
was produced and purified from bacteria (II.2.8.1). Non-labeled FM1, FM3 or FM4 antibodies were diluted 
1:2000 and coated on microtiter plates as primary antibody, then bacterial E1 protein was captured (added in 
PBS to a final volume of 100μl), then the mAbs labeled with HRP were added in final volume of 100μl as 
secondary antibody (1:800). ELISA readings (OD405 nm) were performed after 30 min incubation with NBT 
substrate at 37°C. Shown are mean values from three independent experiments. Standard deviations are shown 
with error bars.  
 
III.8.2    HCV-E1 detection in patient serum using FM1 and FM3HRP monoclonal 
antibodies 
Most patients with an acute or cleared HCV infection develop antibodies against the envelope 
glycoprotein E1. Therefore, the generated mouse monoclonal antibodies were tested to detect 
the viral E1 glycoprotein in patient samples. Furthermore, the produced recombinant E1 
protein in bacteria and plant were used to detect the anti-E1 human antibodies of patient 
serum. In the first approach, the efficiency of the diagnostic tools could be able to 
discrimination between acute and cleared infection that should be possible by detecting HCV 
antigen in the blood of HCV patients. The previous results from the s-ELISA setup were 
revealed the combination of FM1 and FM3HRP, which were the optimum for detecting the 
recombinant E1 protein, so using this combination with different serum dilutions (1:20 and 
1:40) were analyzed for the existence of E1. Figure 33 showed the high reactivity between the 
mAb FM1 used as primary antibody and FM3 used as secondary antibody in s-ELISA. The 
assay was giving strong specificity to detect the HCV-E1 glycoprotein in patient serum in all 
cases under this study. This assay confirmed the results formerly obtained by the Abott 
ARCHITECT® anti-HCV assay, Moreover, the regular correlation with the serum dilution, no 
reaction between the negative control (non infected sample) and the GST protein (unrelated 
protein to detect cross reactivity) was observed with the monoclonal antibodies. 
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Figure 33: Reactivity of selected HCV-E1 monoclonal antibodies to HCV infected patient serum in s- 
ELISA (II.2.3.5). HCV-E1 mouse monoclonal antibody FM1 (unlabeled) (II.2.4.5)  was coated 1:2000 dilution 
and 100 µl of infected patient serum 1:20 (blue), 1:40 (red) (II.2.8.2) was added. The ELISA plate was blocked 
for 0.5 h at RT, and then incubated with monoclonal antibody FM3 labeled with HPRO (II.2.4.6) for 1h. ELISA 
readings (OD405 nm) were performed after 30 min incubation with NBT substrate at 37°C. Shown are mean 
values from three independent experiments. Standard deviations are shown with error bars.  
 
III.8.3 Detection of human HCV-E1 antibodies from patient serum using 
recombinant E1 protein produced in bacteria or plant. 
The patients with an acute or cleared HCV infection develops antibodies against the envelope 
glycoprotein E1, Furthermore, it was tested if the expressed E1 protein from bacteria and 
plant can be used to detect anti-E1 antibodies of HCV patient. As a second approach, initially, 
human antibodies from serum HCV patient with genotype 1b were analyzed by direct ELISA 
assay, with the recombinant E1 protein produced in bacterial and plant coat microtiter plates 
(100 ng/well) by different dilutions of human serum from infected patients with HCV 
genotype 1b. Then the rabbit-anti human antibody was added as a secondary antibody for 
detection (Figure 34), the samples showed a specific binding to the E1 protein produced in 
bacteria and plant. The results revealed there were cross reactivity with three samples with the 
E1 protein produced in plant, where signal had got with low load virus samples, reversing the 
results from interaction between E1 produced in bacteria where the cross reactivity was very 
low. This assay confirmed the results formerly obtained by the Abott ARCHITECT® anti-
HCV assay, 
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Figure 34: Reactivity of human HCV antibody to recombinant E1 protein produced in bacteria or plant in 
direct ELISA. Binding of human HCV antibodies to recombinant E1 protein produced in bacteria or plant was 
evaluated by direct ELISA (II.2.8.1). 100ng/well of E1 protein (II.2.3.5) was coated on microtiter plates. 
100ng/well human HCV antibodies were added in PBS to a final volume of 100μl. Bound human HCV 
antibodies were detected by addition of 1:5000 diluted goat-anti human polyclonal antibodies conjugated to 
alkaline phosphatase as secondary antibody. ELISA readings (OD405 nm) were performed after 30 min 
incubation with NBT substrate at 37°C. Shown are mean values from three independent experiments. Standard 
deviations are shown with error bars.  
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IV Discussion 
IV.1 Bacterial production and purification of full size and truncated HCV-E1 
proteins  
The first objective of this project was to produce, in bacteria,a full-size recombinant E1 
protein from HCV type 1b as well as truncated fragments of the same protein. The proteins 
were expressed in Escherichia coli, purified by IMAC and used to immunize mice. This 
allowed the isolation of antibodies from hybridoma cultures for epitope mapping and later 
development as diagnostic reagents. E. coli is the preferred bacterial host for the production of 
heterologous proteins because well-characterized and robust strains have been developed that 
grow rapidly and have simple culture requirements [114]. The membrane-associated E1 
protein has some distinctive features, such as resistance to alkaline and salt extraction, and the 
presence of membrane anchors at the C-terminus. When the protein was initially expressed in 
E. coli, this hydrophobic region increased membrane permeability and was toxic to the 
bacteria [115,116]. However, because this region also interacts with the signal recognition 
particle, its removal led to improve the production of insoluble E1 protein that accumulated in 
the periplasmic space as inclusion bodies. A protocol was therefore established to induce 
protein production with using IPTG as inducing reagent [117]. And this protocol was 
followed to produce the E1 proteins described in this project (II.2.2.1). Full lenght E1 and its 
fragments were expressed in the periplasmic space and purified from bacterial cells by IMAC 
on a Ni-NTA column. The yield of full size protein was 0.28 mg/L (2.3 mg purified protein 
from a 10-L culture) and the yield of the fragments was 0.70-0.77 mg/L (3.7-4.9 mg total 
purified protein). ELISA was used to evaluate the protein yields before and after purification, 
indicating that some protein was lost during the purification process [118, 119]. Several steps 
were taken to increase yield of full size E1, including codon optimization (for normal strains 
without additional tRNAs) and the testing of alternative signal peptides [120]. Fusion tags 
were also used to stabilize the protein and/or increase its solubility [121]. The prokaryotes can 
produce correctly folded recombinant E1 protein in the periplasmic space, but the yield 
declines in proportion to the number of disulfide bonds [122]. Growth conditions such as 
temperature and cultivation period were optimized, and cytosolic expression was tested as an 
alternative to periplasmic accumulation [123]. The hydrophobic region of the E1F6 truncated 
fragment might be responsible for the lack of expression. HCV envelope glycoproteins are 
retained in the ER and the presence of lysine-rich amino acids before the retention signals in 
the transmembrane domain. An additional ER retention signal could therefore be present in 
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the E1 ectodomain [124]. The full size E1 protein and truncated derivatives were expressed 
successfully in the bacterial system and purified using a His6 fusion tag (II.2.2.1). This is 
recommended for fusion proteins expressed in E. coli because as well as facilitating 
purification, the fusion tag can also increases the solubility of target proteins [125]. Initial 
results suggested that large amounts of the fusion proteins were nevertheless accumulating as 
insoluble aggregates (inclusion bodies) that were discarded with the cell debris. The yield of 
soluble, correctly folded protein was improved by modifying the culture and induction 
conditions, e.g. reducing the IPTG concentration to 0.5 mM, increasing the induction time to 
16 h and reducing the temperature to 26°C after induction, thus preventing the formation of 
aggregates. Lower temperatures have been shown to reduce inclusion body formation in many 
studies, but reducing them too much (e.g. incubation at 15-20°C) has no further positive 
impact on protein folding but does reduce the rate of transcription and translation [126]. When 
BL21-DE3 bacterial cells were used with pET26b (+) as the expression vector, no functional 
E1 protein should theoretically be present in the cytosol, where it would have access to death 
cascade substrates. SDS-PAGE and western blot analysis showed that the E1 proteins were 
largely intact, but after purification and dialysis some of the E1 protein was degraded. 
Optimized expression and purification conditions were unable to prevent this loss of integrity. 
The degradation of recombinant proteins is typically caused by intracellular proteases [127]. 
The premature termination of protein synthesis, proteolysis is a regulated physiological 
process that is requires for the removal of incorrectly folded and abnormal proteins [76].  
IV.2    Generation and characterization of E1-specific monoclonal antibodies 
IV.2.1     Immunization of mice and monoclonal antibody production 
HCV-E1 specific antibodies were generated by injecting the recombinant E1 protein 
subcutaneously into BALB/c mice [128]. Serum analyzed by ELISA using the E1 antigen as a 
substrate revealed the presence of IgG1 antibodies in the murine immune system [129]. 
Several other studies have shown that the E1 antigen can trigger a strong immune response 
and generate high titers of IgG antibodies [61]. Four hybridoma clones were identified, 
producing monoclonal antibodies F39, FM1, FM3 and FM4, each of which was shown by 
ELISA to bind specifically to E1. The ability of the antibodies to recognize different truncated 
E1 derivatives indicated that several different epitopes were involved, and that each antibody 
bound strongly to a limited number of residues [130]. The quantity of antibody that can be 
obtained by purifying the culture supernatant collected from hybridoma cultures is 1-100 
µg/ml [131], and the yield produced by affinity purification in this project was ~10 mg/L. 
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Long-term hybridoma culture with multiple passages generally results in a heterogeneous cell 
population producing multiple antibodies with different specificities, or the complete loss of 
antigen binding activity [132]. The variable domains of monoclonal antibodies FM1, FM3 
and FM4 were aligned and shown to represent three distinct open reading frames with many 
differences in the heavy and light chain CDRs. The heavy chain CDR1 was different with the 
exception of two conserved residues. Only one residue was lacked in the CDR2 of antibodies 
FM3 and FM4, whereas two were lacked in FM3 CDR3. In the light chains, CDR1 and CDR2 
had different sequences in each antibody and the sequence of CDR3 was different with the 
exception of one conserved residue. Differences in the framework regions did not affect the 
ability of each antibody to bind recombinant E1 protein in ELISAs [133]. Western blots and 
ELISAs showed that FM3 had greater specificity for the recombinant E1 protein than FM1 
and FM4, suggesting the corresponding epitopes were not present at the N-terminus. The 
ability of each antibody to bind denatured E1 in western blots indicated they recognize linear 
epitopes. A highly-conserved epitope is found at the C-terminus of E1, and most variation is 
found at the N-terminus [134]. By recognizing a conserved epitope, each of these antibodies 
is a good candidate for development as a diagnostic reagent for the detection of HCV in 
patient blood samples. 
IV.2.2     Epitope mapping of FM1, FM3 and FM4 
The overlapping fragments of recombinant E1 (named E1F1 to E1F5) were used to map the 
epitopes recognized by antibodies FM1, FM3 and FM4 and to identify the major linear 
antigenic regions within the HCV E1 protein. Relatively little is known about the HCV E1 
protein because it has been difficult to produce in heterologous systems [135]. Antibodies 
against E1 can prevent HCV from binding to receptors of liver cells, thus inhibiting infection, 
suggesting the corresponding epitopes on E1 are necessary for virus uptake [136]. Mouse 
polyclonal antibodies raised against modified genotype 1a HCV E1 can neutralize HCV 
genotype 2a [133] and HCV neutralization by monoclonal antibodies directed against E1 has 
been confirmed in the chimpanzee model. At least two regions of E1 are believed to contain 
putative neutralization epitopes. The N-terminal epitope (amino acids 192-202) was identified 
by mapping the specificity of monoclonal antibody H-111, which was recovered from a 
patient chronically infected with HCV genotype 1b. In ELISAs, this antibody was able to bind 
E1 protein from genotypes 1b and 2b [136]. The C-terminal epitope (amino acids 315-328) is 
fully conserved apart from the residue at position 324, which is partially conserved [137]. 
FM1 and FM4 were shown to bind the E1F5 fragment (amino acids 322-353) whereas FM3 
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bound to the E1F1 fragment (amino acids 191-252). Fragment E1F5 does not contain any 
cysteine residues and fragment E1F1 has only a single cysteine near the N-terminus. Neither 
fragment is therefore capable of forming intramolecular disulfide bonds, which means the 
antibodies must recognize linear epitopes. FM1 and FM4 may recognize the same epitope or 
different epitopes in the same fragment E1F5 (based on the significant differences in their 
CDRs). H-111 and murine 3D5/C3 also bind linear epitopes, which is probably the case for 
FM3 because the mice were immunized with a non-glycosylated, denatured form of E1 [136]. 
The H-111 and FM3 variable regions were compared. This revealed only 40% identity in the 
heavy chain variable region, with no conserved residues in the CDRs, but 67% identity in the 
light chain variable region with only a few differences in the CDRs [138]. Most of the 
distinctions can be explained by the different framework regions when comparing human and 
murine antibodies, whereas the high similarity within the CDRs suggests the recognition of a 
similar epitope. For further comparison, it would be interesting to analyze the kinetics of each 
antibody and to determine whether either can block the binding of E1-E2 heterodimers to 
hepatocytes, which is mediated by E1 amino acids 192-211. The distribution of antibodies 
with respect to this conserved E1 epitope in various populations also suggests a role for 
serologic differences in the immune response to HCV. Carriers with a prevalence of such 
antibodies were found among blood donor populations around the world [139]. In conclusion, 
I have in this study identified linear antigenic regions within the HCV E1 protein, proving 
insight into the structure and function of the E1 protein because these regions are likely to be 
exposed on the surface and involved in HCV uptake into target cells. These regions could be 
developed as peptides with anti-HCV activity, e.g. by competitive blocking of cellular 
receptors. 
IV.2.3 Generation of the E1-specific scFv-FM3 fragment  
Monoclonal antibody FM3 was chosen as the basis for the scFv-FM3 antibody fragment 
because it had the highest binding activity of the four candidates. Instead of perpetuating B 
cells producing full size monoclonal antibodies, the genes for the heavy and light chain 
variable regions were used to create a single-chain fragment with the same specificity, which 
can be expressed in E. coli [140]. The scFv-FM3 antibody was produced in HB2151 
suspension cells under IPTG induction and purified using a standard, optimized process. The 
scFv-FM3 gene was joined to a leader peptide sequence in vector pKFsc for export to the 
periplasmic space, which allows the formation of disulfide bonds and the accumulation of 
soluble recombinant proteins, since the production of functional recombinant antibody 
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fragments in E. coli was first demonstrated [141]. This facile system has been used to produce 
antibodies for many different applications, ranging from immunochemical analysis to the 
production of novel antibody-based therapeutics [142]. The expression levels that can be 
achieved for scFv antibodies vary widely, the norm being ~1mg/L [140]. Although the use of 
leaky promoters such as lac may result in low scFv expression levels, the primary sequence of 
the variable domains is the main influential factor because it affects the folding efficiency of 
scFv fragments [143]. The expression of recombinant scFv in E. coli is a robust technology 
because non-glycosylated scFvs produced in bacteria can be used directly in virus 
neutralization assays. The success of scFv expression in E. coli depends on the properties of 
the variable domain, and expression levels can vary widely for different antibody fragments 
[144]. Mutations introduced into the N-terminal part of heavy chain framework region 1 
(FR1) during PCR-based cloning with degenerate primers can significantly reduce the yield, 
stability and antigen binding capacity of recombinant antibodies [145]. 
IV.3 Production and characterization of E1 and scFv-FM3 in tobacco 
plants 
The E1 and scFv-FM3 proteins were produced in tobacco by transferring the corresponding 
genes into plant expression vectors that targeted the proteins to the ER or apoplast. 
Previously, scFvs have been produced in bacteria. Usually the scFvs are relatively easy to 
fold, they have even been expressed successfully in the reducing environment of the plant 
cytosol [146]. The pTRAkc-scFv-FM3-ER construct was designed so that the scFv was 
retained in the ER. This was achieved by introducing a C-terminal KDEL tag for ER 
localization [147]. The scFv-FM3 protein was retained in the ER and might bound to E1 
protein present in the same compartment. Targeting to the secretory pathway was achieved by 
the inclusion of an N-terminal signal sequence, which promotes cotranslational transfer 
through the ER membrane. The origin of the signal sequence is not critical because sequences 
from plants, mammals and yeast all function correctly [148]. For scFv-FM3, the leader 
sequence was derived from the light chain of a murine antibody. The addition of stabilizing 
amino acids may also improve the functionality of specific immunoglobulins lacking disulfide 
bonds [149]. E1 protein was also expressed in tobacco but this protein has not been expressed 
in plants before. The expression of E1 protein in plants was therefore the second objective of 
this project. The yield of E1 in plants was investigated for increase the yield by coexpressing 
the E1 protein with scFv-FM3 to form a complex, then purified by IMAC. Detailed 
quantitative analysis was performed to compare the yields of the antigen and scFv in plants 
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and bacteria. The yield of scFv-FM3 accumulating in the ER of tobacco plants was 3.1 mg/kg 
compared to 4.8 mg/kg for E1. Although many scFvs accumulate at low levels, targeting them 
for retention in the ER can improve the overall yields. This exploits the protein sorting and 
targeting mechanisms used by plant cells to transport endogenous proteins to specific 
organelles. It has been experimentally confirmed in plants that antibodies directed to the 
secretory pathway for assembly and post translational processing are secreted into the 
apoplast [150]. The ER retention provided the highest yields of both E1 and scFv-FM3, 
producing 30-fold more E1 protein and 10-fold more scFv-FM3 than was possible in E. coli. 
The recombinant proteins expressed in tobacco plants were generally intact. Some 
degradation was observed in the case of ER-targetedscFv-FM3 resulting in two closely-placed 
bands on western blots. No significant increase in yields was observed in leaves that were co-
agroinfiltrated with the E1 and scFv-FM3 constructs, nor were there any differences over a 
range of incubation times (2, 4 and 6 days). The scFv-FM3 antibody had a framework well 
adapted for ER accumulation [151]. Western blot analysis of trapped raw protein extracts 
from tobacco leaves showed that both the E1 protein and scFv-FM3 were present in the ER. 
However, it was impossible to produce both in the apoplast, might be the chaperones that 
located in the ER helps to improve the recombinant protein [152]. Even so, since most of the 
vector sequences in each construct were the same, and the genomic distribution of the four 
constructs should be statistically identical, it is unlikely that transcriptional gene silencing 
TGS occurred solely in plants transformed with apoplast-targeting constructs. Furthermore, 
transgene expression after transient transformation does not necessarily require T-DNA 
integration into the plant genome [153]. The half-life and instability index proteins can be 
estimated using the ProtParam tool on the ExPASy server 
(http://www.expasy.ch/tools/protparam.html). Using this approach, the predicted half-life of 
the E1 protein was 18 h in mammalian reticulocytes, 55 min in yeast, and >11 h in E. coli, 
earning classification as an unstable protein. In contrast that the predicted half-life of scFv-
FM3 was 24 h in mammalian reticulocytes, >19 h in yeast, and >12 h in E. coli, earning 
classification as a stable protein. However, this does not explain why the E1 protein plus His6 
tag was not detected in the ER, whereas scFv-FM3 plusHis6 tag was easily detected by 
western blot using anti-His antibodies. Although the tobacco-derived E1 could not be detected 
with anti-His antibodies, monoclonal antibodies FM1, FM3 and FM4 were all capable of 
detecting the antigen and showed high binding specificity. Indeed, FM3 bound to its target 
within 30 s, much faster than the other antibodies, and with a higher signal to noise ratio. The 
production of E1 protein could also be affected by the well-known phenomenon of ER stress, 
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which reflects an imbalance between the rate of protein synthesis in the cytosol and the rate of 
protein folding in the ER [154]. 
IV.3.2 Binding between scFv-FM3 and recombinant E1 protein 
The binding of purified monoclonal antibodies to recombinant E1 protein was tested by direct 
ELISA. The results showed the FM1, FM3 and FM4 detected up to 500 ng of protein per ml 
of each antibody. The detection curve was linear between 1000 and 500 ng/ml. FM3 bound 
more strongly to its antigen than the other antibodies, hence the choice of this antibody to 
develop the scFv variant. Patients generally mount an IgG antibody response to E1 during 
HCV infections [155]. HCV-specific antibodies that detect virus particles by ELISA could be 
developed into novel diagnostic reagents or therapies. Most therapeutic antibodies have been 
developed using classic hybridoma technology, but the high costs and long development 
times have encouraged the use of scFvs as an alternative [156]. Hybridomas are unsuitable for 
large-scale production, so recombinant antibodies with the desired specificity are produced in 
heterologous systems such as bacteria and plants. Here, scFvs are advantageous because they 
are single proteins that fold easily, and glycosylation is not usually required, allowing 
production in bacteria. Highly parallel expression formats allow bacteria to be used to screen 
scFvs and isolate those with the greatest affinity for the antigen. The efficient folding of scFvs 
makes them particularly suitable for large-scale production in plants [150]. Specific 
interactions between scFv-FM3 and the E1 protein produced in bacteria and plants were 
confirmed by direct ELISA, with the plant-derived antigen binding with twice the efficiency 
perhaps suggesting an important role for protein folding. Differences in binding efficiency 
could also reflect the different sensitivities of the detection antibodies recognizing the His6 
and myc tags. There was little or no cross-reactivity between scFv-FM3 and endogenous 
proteins in the control sample. 
IV.4 Detection of recombinant E1 protein by sandwich ELISA 
The relative importance of humoral and cellular immunity in the prevention and/or clearance 
of HCV infections is controversial and poorly understood. Many studies suggest that cellular 
immunity has the most important role in clearance, and possibly also in the prevention and 
modification of HCV infections. However, there is also a large body of evidence suggesting 
that antibodies help to prevent and even resolve HCV infections, e.g. antibodies can neutralize 
HCV [136]. Little is known about the immune response to the HCV E1 glycoprotein, 
although two regions containing putative neutralization epitopes have been identified. One of 
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these was mapped with antibodies to the C-terminus of protein E1 from HCV genotype 1b 
[157]. and the other was identified by interaction with three murine monoclonal antibodies 
generated against recombinant E1 protein. These antibodies do not interact with the core HCV 
protein. The best combinations of antibodies for the detection of E1 protein by sandwich 
ELISA was FM1/FM3HRP, and this was used to develop a sandwich enzyme-linked 
immunosorbent assay (s-ELISA) for the detection of HCV in patient serum. The assay was 
sensitive enough to detect approximately 1.0 ng of E1 antigen (0.62-40 ng of the pure 
protein). There was no interaction between the antibodies and a control protein, GST.HRP 
labeling was used predominantly to monitor the murine monoclonal antibodies against 
recombinant E1 protein produced in bacteria [158]. The yield of E1 in E. coli correlated well 
with that of the first monoclonal antibody. The s-ELISA therefore appears to be a simple, 
quantitative method to determine the abundance of protein E1, suitable for the high-
throughput analysis of acute HCV infections. The method was used to optimize E1 production 
in E. coli. [159].A commercially available immunoassay for HCV patient serum based on E1 
detection uses E1-specific monoclonal antibodies or E1 proteins containing multiple epitope 
fusions [58, 160]. The sandwich ELISA is suitable as a tool for the quantitative determination 
of HCV loads serum, based on the detection of E1. However, quantitation of the antigen is 
complicated by the protein binding to the surface of ELISA plates, so it is important to screen 
the assay components to avoid cross-reactivity with other proteins [161]. The detection of 
early-stage HCV infections is challenging, but this s-ELISA format is a promising approach 
that may allow infections to be confirmed at an earlier stage without recourse to the more 
expensive and also more error-prone RT-PCR assays. The amount of E1 antigen increases 
linearly with the virus load providing a sound basis for HCV diagnosis [100].  
IV.4.1    Detection of E1 glycoprotein in patient serum using FM1 and FM3HRP 
New diagnostic tests are required for the early detection of E1 antigen in the plasma of HCV 
patients, because although effective tests based on E1 have already been demonstrated [162]. 
they suffer from a number of limitations, including a high frequency of false-positive and 
false-negative results [163]. In this project, serum from HCV patents was tested for the E1 
antigen using the novel s-ELISA platform, and the assay was shown to be 10-fold more 
sensitive. This potentially would allow the detection of HCV infections with minimal 
equipment during medical consultations in health care centers. The sensitivity of the FM1 and 
FM3HRPused in the s-ELISA is significantly higher than the polyclonal antibodies used in 
current tests [164]. The new antibodies were unable to detect 50 copies of HCV per ml of 
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serum in patients 5 and 16, but detected 103-105 copies/ ml and gave a strong signal in 
response to 106-107 copies/ ml with the dilution 1:20 and 1:40. There was no response in the 
control sample. These data suggest that the antibodies are suitable as the basis for novel HCV 
diagnostic tools. Sandwich ELISA is usually the method of choice for the sensitive and 
accurate detection of proteins and lipoproteins in serum, which is required for chronically-
infected HCV patients, and those in the acute disease phase [165]. This sensitivity allows 
diagnostics based on the detection of E1 antigen to be used for the accurate laboratory 
diagnosis of HCV [94]. Previous studies have demonstrated that a diagnostic strategy based 
on the E1 antigen provides a sensitivity of about 80% [166]. The new test, using two 
monoclonal antibodies to capture and quantify the E1 antigen, increases the sensitivity to 
99%, and it would be interesting to evaluate this as a diagnostic tool using clinical samples 
[166]. The potential for false positives was addressed in a recent study that aimed to 
determine the HCV load in serum from patients infected with HCV type 1b [96]. The 
quantitative data were positively correlated but the absolute values differed significantly, 
suggesting that ensuring accuracy may be a challenge. Antibody specificity is important in 
immunological assays such as s-ELISA [167]. 
IV.4.2    Detection of HCV-specific antibodies in serum by ELISA 
The next objective was to evaluate a direct ELISA method for HCV diagnosis based on the 
detection of antibodies specific to the E1 glycoprotein. A new test was developed 
incorporating one or more synthetic peptides, including one from the structural region of the 
E1 protein. This method is accurate for the diagnosis of acute phase HCV infections [168]. A 
few studies have also been published using only one structural antigen, since antibodies 
against structural proteins appear much earlier more than antibodies against the non-structural 
region of HCV and would therefore give a more robust correlation [169]. The recombinant E1 
proteins produced in bacteria and plants were evaluated for the detection of HCV antibodies 
in 39 serum samples submitted for routine anti-HCV screening. The recombinant E1 protein 
was recognized by anti-HCV IgG antibodies in all the samples, indicating 100% sensitivity. 
There was a correlation between the mean titers of OD/cut-off determined by ELISA and the 
presence of viremia, suggesting that patients with high titers of anti- E1 antibodies are most 
likely to be viremic. Further studies with larger numbers of patients are necessary to confirm 
these findings. The determination of OD titers as above may therefore offer an alternative to 
RT-PCR, particularly in places where the latter test is not widely available. Measurements of 
anti-E1 antibodies may offer a better diagnosis than viral load and in chronic HCV infections 
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may reveal the ability of viral proteins to assemble into particles [170]. The usefulness of the 
test depends on the prevalence of HCV antibodies in the population, which may be very low, 
and anti-HCV ELISA reactivity should be tested using recombinant immunoblot assays [171]. 
Affinity-purified antibodies recognizing recombinant E1 protein produced in plants can be 
used to detect the E1 glycoprotein in serum samples from infected patients, and the absence of 
a cross reaction with GST suggests that endogenous proteins should not be detected. The E1 
glycoprotein contains several linear epitopes, particularly those between residues 191 and 
252, and between residues 322 and 353. Affinity-purified antibodies binding to the 191-252 
region can be used to detect the E1 cleavage product, whereas antibodies to both regions can 
be used to detect the intact protein. ELISAs are based on the principle that immobilized 
antigens can be detected using a complementary antibody labeled with an enzyme that acts on 
a chromogenic substrate [169]. The accuracy of detection methods can be compared by 
evaluating their diagnostic indices, namely sensitivity, specificity, predictive positive value 
and predictive negative value [167].Traditional antibody detection methods do not distinguish 
between the IgG and IgM responses, and diagnosis was based either on seroconversion, or a 
significant rise in antibody titer when comparing acute and chronic samples [166]. The 
method developed in this project indicated a specific reaction between the E1 antigen and 
antibodies in humans. Positive results were obtained in serum samples that were positive and 
negative for HCV RNA, so the test cannot determine whether a patient carries infectious virus 
particles. High anti-E1 antibody titers can, however, be related to the replicative phase of the 
infection. Our results suggest that combining the tests for E1 antigen and anti-E1 antibodies 
could increase the sensitivity of the HCV diagnostic assay. The appearance of neutralizing 
antibodies is delayed, and only IgG1 antibodies are found in patients with chronic infections 
[172]. However, our tests allow the virus to be detected during the acute phase. The ELISA 
format has many advantages in a diagnostic setting, i.e. it is simple, easy to automate, 
inexpensive, sensitive and accurate. Conventional vaccination approaches to neutralize HCV 
by inducing antibodies that target glycoprotein E1 have shown only limited success. In 
chimpanzees, immunization with recombinant E1 glycoprotein protected the animals from a 
challenge with a homologous virus, but was not sufficient to achieve virus clearance in 
existing infections. The intramuscular injection of a truncated recombinant HCV-E1 protein 
was well tolerated in chronic hepatitis C patients, but overall these therapeutic vaccination 
strategies appear to hold promise. 
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V Summary 
This project resulted in the successful production and purification of full size recombinant 
HCV E1 protein in bacteria, allowing the generation of three specific monoclonal antibodies. 
Five truncated fragments of the same protein were also produced in bacteria, allowing the 
epitope recognition of the new antibodies to be mapped. Specific epitopes within the E1 
protein were identified for FM1, FM3 and FM4.  
Periplasmic expression of full size E1 resulted in a yield of 2.3 mg purified protein, whereas 
the yield of the truncated fragments ranged from 3.7 to 4.9 mg. The recombinant E1 protein 
was injected subcutaneously into BALB/c mice to generate the three E1-specific antibodies 
using hybridoma technology. ELISAs revealed that FM3 had the strongest binding activity of 
the three antibodies and that all three, by virtue of their ability to bind denatured proteins, 
recognized linear epitopes.  
FM1 and FM4 reacted with the E1F5 fragment (residues 322-353), whereas FM3 reacted with 
the E1F1fragment (residues 191-252). Neither fragment possessed two cysteine residues 
indicating that neither epitope included a disulfide bridge. FM1 and FM4 bound to fragment 
E1F5 with similar affinity, although it is not clear whether they recognize exactly the same 
epitope as the CDRs are very distinct. FM3 bound with much higher affinity to its epitope 
suggesting it would the ideal basis for a diagnostic reagent. 
The variable regions of FM3 were used to construct scFv-FM3, which was expressed in E. 
coli and processed to yield a highly pure preparation. The same variable antibody regions 
were expressed in plants, and it was found that targeting to the ER resulted in 30-fold higher 
yields than achieved in bacteria. The E1 protein was also expressed in plants, with 10-fold 
higher yields than achieved in bacteria. Neither E1 nor scFv-FM3 was recovered from the 
plant apoplast.The scFv-FM3 antibody was able to bind bacterial and plant-derived E1 protein 
as shown by direct ELISA, but binding to the plant-derived E1 protein was twice as efficient. 
There was little or no cross reactivity between scFv-FM3 and HCV core protein as a control.  
The best combination of antibodies for the s-ELISA was FM1/FM3HRP. In serum samples, 
viral loads correlated with the s-ELISA signal revealing a viral load of fewer than 50 
copies/ml in patients 5 and 16 (no response), 103-105 copies/ml (good response), and 106-107 
copies/ml (good response, with 1:20 and 1:40 dilution). There was no signal with the control 
protein.  
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Assays based on the recombinant E1 protein produced in bacteria and plants separately were 
used to test 39 serum samples from infected HCV patients for the presence of anti-HCV 
antibodies. Antibodies were detected in all the patient samples, indicating the antibodies can 
achieve 100% sensitivity because antibodies were not detected in all samples that tested 
positive for virus RNA. 
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VI Appendix 
VI.1 List of Abbreviations 
°C degree Celsius 
$ US Dollar 
% percentage 
 Wavelength 
A adenine 
aa amino acid(s) 
Ab antibody 
ALT Alanine aminotransferase 
Amp ampicillin 
ampr ampicillin-resistant 
AP  alkaline phosphatase 
APC Antigen presenting cell 
A. tumefaciens Agrobacterium tumefaciens 
BCIP  5-bromo-4-chloro-3-indolyl phosphate 
bp  base pair 
BSA  bovine serum albumin 
C  cytosine 
CaMV  Cauliflower mosaic virus 
Cb  Carbenicillin 
CB  coating buffer  
CDR  complementarity determining region 
CH constant region of light chain 
CL constant region of light chain 
CHS  Chalcone synthase 
CTL Cytotoxic T cell 
cv.  Cultivar 
Da  Daltons, g/mol 
DC dendritic cell 
DMSO  dimethylsulfoxide 
DNA  desoxyribonucleic acid 
dNTP  deoxynucleotide triphosphate 
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DT  diphtheria toxoid 
DTT  dithiothreitol 
E. coli Escherichia coli 
EDTA  ethylenediaminetetraacetic acid 
ELISA  enzyme-linked immunosorbent assay 
ER  endoplasmic reticulum 
Fc  “Fragment crystallizable” 
FSH  follicle-stimulating hormone 
G  glycine 
GAM  goat-anti-mouse (antibodies) 
GnRH  gonadotropin releasing hormone 
gm  gram 
h  hour(s) 
HBS  Hepes buffered saline 
HCC hepatocellular carcinoma 
His  histidine 
HPLC  high pressure liquid chromatography 
IFN-α interferon-alfa 
IgG  immunoglobulin G 
KA equlibrium association constant 
kDa  kilodalton 
kg  kilogram 
Ki inhibitory constant 
Km  Kanamycin 
L  liter(s) 
LBA  Luria broth with ampicillin 
M  molarity (mol/L) 
mAb  monoclonal antibody 
MHC major histocompatibility complex 
min  minute(s) 
mRNA  messenger ribonucleic acid 
MSMO  Murashige and Skoog medium with minimal organics 
MW  molecular weight 
NBT  nitro blue tetrazolium 
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nm nanometer 
OD  optical density 
PAGE  polyacrylamide gel electrophoresis 
PBS  phosphate buffered saline 
PBST  phosphate buffered saline containing 0.05% Tween20 
PCR  polymerase chain reaction 
rAb  recombinant antibody 
Rif  Rifampicin 
rpm  rotations per minute 
RT  room temperature 
scFv  single chain Fragment variable 
SDS  sodium dodecylsulfate 
SOE  splicing by overlap extension 
Taq  Thermus aquaticus 
TCR T cell receptor 
T-DNA  transfer DNA 
TLR toll like receptor 
TMV Tobacco mosaic virus 
Tris trishydroxymethylaminomethane 
U unit 
UTR  untranslated region 
UV  ultraviolet 
V  Volt 
VH variable region of antibody heavy chain 
VL variable region of antibody light chain 
v/v  volume per volume 
v/w  volume per weight 
w/v  weight per volume 
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VI.2 Nucleic acid and amino acid sequence of HCV-E1 and scFv-FM3. (Figure 
35) 
 
Nucleic acid of HCV-E1 (Length 499 bp) 
 
1   ccatggccta ccaagtgcgc aacgcgtccg gggtgtacca tgtcacgaac gactgctcca 
61  actcaagtat tgtgtatgag gcggcggacg tgattatgca cacccccggg tgcgtgccct 
121 gcgtccggga gaacaattcc tcccgctgct gggtagcgct cactcccacg cttgcggcca 
181 ggaacagcag catccccact acgacaatac ggcgtcatgt cgacttgctc gttggggcag 
241 ctgctctctg ttccgctatg tatgtggggg atttttgcgg atctgttttc ctcgtctccc 
301 agctgttcac tttctcacct cgccggtatg agacggtgca agactgcaat tgctcaatct 
361 atcccggcca tgtatcaggc catcgcatgg cttgggatat gataatgaat tggtcaccta 
421 caacagccct agtggtatcg cagctactcc ggatcccaca agccgtggtg gatatggtgg 
481 gccgggccca gcggccgc 
 
 Amino acid sequence of HCV-E1 (Length 194 aa) 
 
1   MRPSRPWPTK CATRPGCTMS RTTAPTQVLC MRRRTALCTP PGACPASGRT 
51  IPPAAGARSL PRLRPGTAAS PLRQAGTAAS PLRQYGVMST CSLGQLLSVP 
101 LCMWGIFADL FSSSPSCSLS HLAGMRRCKT AIAQSIPAMY HQLLNLSRPC 
151 IRPSHGLGYD NELVTYNSPS GIAATPDPTS RGGYGGRGPR GHSS 
 
 Nucleic acid of scFv-FM3 sequence 
 
1    atg gcg gaa gtg cag ctg cag cag agc ggc gcg gaa ctg gtg cgc   45 
46   agc ggc gcg agc gtg aaa ctg agc tgc acc gcg agc ggc ttt aac   90 
91   att cag gat tat tat att cag tgg gtg aaa cag cgc ccg gaa cag   135 
136  ggc ctg gaa tgg att ggc tgg att gat ccg gaa aac ggc gat acc   180 
181  gaa tat gcg ccg aaa ttt cag ggc aaa gcg acc atg acc gcg gat   225 
226  acc agc agc aac acc gcg tat ctg cag ctg agc agc ctg acc agc   270 
271  gaa gat att gcg gtg tat tat tgc aac gcg tgg gaa acc gtg att   315 
316  acc acc gtg ctg gat tat ccg atg gaa tat tgg ggc cag ggc acc   360 
361  agc gtg acc gtg agc agc aac ctg att aaa ggc ggc ggc agc ggc   405 
406  ggc ggc agc ggc ggc ggc agc ggc gcg ccg gtg gat att gtg ctg   450 
451  acc cag agc ccg gcg agc ctg gcg gtg agc ctg ggc cag cgc gcg   495 
496  acc att agc tgc aaa gcg agc cag agc gtg gat tat gat ggc gat   540 
541  agc tat atg aac tgg tat cag cag aaa ccg ggc cag ccg ccg aaa   585 
586  ctg ctg att tat gcg gcg agc aac ctg gaa agc ggc att ccg gcg   630 
631  cgc ttt agc ggc agc ggc agc ggc acc gat ttt acc ctg aac att   675 
676  cat ccg gtg gaa gaa gaa gat gcg gcg acc tat tat tgc cag cag   720 
721  agc aac gaa gat cgc acc ttt ggc ggc ggc acc aaa ctg att aaa   765 
766  cgc 
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Amino acid sequence of scFv-FM3  
 
MAEVQLQQSGAELVRSGASVKLSCTAS GFNIQDYYIQWVKQRPE
QGLEWIGWMSDPENGDTE-YAPKFQGKATMTADTSSNTAYLQLSSL
TSEDIAVYYCNAWETVITTVLDYPMEYWGQGTSVTVSS NLIKGG
GSGGGSGGGSGAPVDIVLTQSPASAVSLGQRATISCKA SQSVDYD
GDSWYQYADYDGA-YKPGQPPKLLIYAASNLESGIPARFSGSGSGTD
FTLNIHPVEEEDAATYYCQQSEDTFGGGDRTFGGGTKLELKR
CDRH1
CDRH2
CDRH3
Linker CDRL1
CDRL2
CDRL3
 
 
VI.3 Vector Maps 
 
Figure 36: Schematic presentation of the vector maps. A: pET26b (+); B: pGEX-5x-3; C: 
pKFsc; D: pCR 2.1 TOPO vector E: pTRAkc map. 
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B 
 
  
Target Gene 
     E1F6 
Nco I 
Eco RI Bam HI 
Xho I 
Not I 
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4974  bps 
P   tac 
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MCS 
amp r pBR322 
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Nar I 
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